Note: Descriptions are shown in the official language in which they were submitted.
CA 02768653 2016-10-31
COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED
COMPOSITIONS
FIELD OF INVENTION
100011 The present invention relates generally to compositions for
topical application
to the skin or hair which comprise metal-complexed peptide fractions of
stressed yeast
extracts, as well as the use of such compositions to provide specific benefits
to the skin or
hair.
BACKGROUND OF THE INVENTION
[0002] Consumers continually seek to improve the appearance of their skin
and hair.
Concerns include visible signs of aging, as well as discoloration or hyper-
pigmentation,
redness and/or inflammation; and over-production of oils and lipids at the
skin surface. Thus
there remains a need for products that provide anti-aging, anti-inflammatory,
anti-lipid and/or
lightening effects.
100031 Skin and hair pigmentation is determined by the level of melanin
present in
the epidermis or hair fiber. Three different types of melanin are present in
the epidermis:
DM-melanin, which is blackish in color; DHICA-melanin, which is brownish; and
pheomelanin, which is reddish in color. Melanin is synthesized in specialized
organelles
called melanosomes within pigment cells (melanocytes), in a process that
begins with the
action of an enzyme, tyrosinase, on the amino acid tyrosine. Melanin synthesis
is regulated
by a number of intracellular factors such as the activity of tyrosinase, the
activity of
micropthalmia-induced transcription factor (MITF), signaling by hormones such
as
melanocyte-stimulating hormone (MSH), oxidative stress, and other factors.
[0004] Inflammation also contributes to skin discoloration and has other
deleterious
effects on the appearance of skin, Ruiz-Maldonado et al. (1997) Semin Cutan
Med Surrg.
1
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
16(1):36-43; Tomita et al. (1989) Dermatologica 179 Suppl 1:49-53. For
example, inflamed
acne lesions can lead to scarring (Holland et al. Semin Cutan Med Surg. 2005
Jun;24(2):79-
83); and the cumulative degenerative effects of inflammation have been shown
to exacerbate
intrinsic (chronological) and extrinsic (photo) aging of human skin. Pillai,
et al. (2005) Int J
Cosmet Sci. Feb;27(1):17-34; Bissett, et al. (1990) Photodermatol.
Photoimmunol. Photamed.
7:153-8; Thornfeldt, CR (2008) J. Cosmet. Dermatol. 7:78-82. A key
inflammatory
mediator, tumor necrosis factor-alpha (TNFa), is believed to be responsible
for both acute
and chronic skin inflammation.
[0005] Collagen
synthesis and degradation also play a role in common skin concerns.
Reduction in collagen I, the collagen type in skin, is associated with loss of
firmness and
elasticity of skin and leads to wrinkling associated with aging. Collagen is
the body's major
structural protein and gives skin strength, durability, and a smooth, plump
appearance. It is
created by fibroblasts, specialized skin cells located in the dermis, in a
process that involves
conversion of preprocollagen Ito procollagen I and eventually to
tropocollagen, the form that
forms collagen fibers. Collagen I is degraded in the skin by matrix
metalloproteinases
(MMPs). Gross J, et al. Biochem Biophys Res Common 1974;61:605-12. MMPs are a
family
of related zinc-dependent proteases, including the metalloproteinases (MMP-1, -
8, and -13)
and gelatinases (MMP-2 and 9).
[0006]
Hyaluronic acid is another component of skin that plays a role in its
aesthetic
appearance. Hyaluronic acid is a glycosaminoglycan (GAG) found in the skin, as
part of the
extracellular matrix (ECM). With age, however, GAG synthesis and overall GAG
skin
content appear to decline. Smith et al. I Invest. Dermatol., 1962, 39, pages
347-350;
Flcischmajer et al. Biochim. Biophys. Acta, 1972, 279, pages 265-275; Longas
et al.
Carbohydr. Res., 1987, 159, pages 127-136. It is believed that this reduction
in GAG
contributes to age-related changes in the skin's mechanical properties,
including, for
example, changes in tissue hydration, as well as plumpness and protection
against free
radicals. Carrino et al., Arch Biochem Biophys. 2000 Jan 1;373(1):91-101;
Vogel et al., Z
Gerontol. 1994 May-Jun;27(3):182-5; Lanir et al., J Biomech Eng. 1990 Feb;
112(1):63-9);
Wiest et al. J Dtsch Dermatol Ges. 2008 Mar;6(3):176-80; Bert et al.
Biorheology. 1998
May-Jun;35(3):211-9.
[0007] The
activity of exfoliating enzymes in the skin also plays a role in its aesthetic
youthful appearance. In the stratum corneum, skin's outermost layer, cell-to-
cell cohesion
depends primarily on proteins known as the corneodesmosomes. During skin
remodeling and
2
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
renewal, dead cells are shed from the skin surface by the action of native
proteases that break
down the comeodesmosomes, thus helping exfoliation. Human tissue Kallikreins
(KLKs) are
a family of proteases that reside in the stratum comeum and are known to be
directly
involved in comeodesmosome turnover. Kishibe M et al. J. Biol. Chem. 2006;
282: 5834-
5841.
[0008]
Overproduction of lipids also affects the appearance of skin, as well as that
of
hair. For example, excess secretion of sebum is associated with oily skin,
hair, and acne; and
excess accumulation of subcutaneous fat can result in cellulite. Cellulite is
a lumpy, uneven
type of fat, that accumulates primarily on the buttocks and thighs and causes
an "orange peel"
or "cottage cheese" look. Lipid metabolism is partly controlled by the
peroxisome
proliferator-activated receptors (PPARs), which form a group of nuclear
transcription factors.
PPAR-gamma (PPAR-y), in particular, is believed to be critical in a feed-
forward pathway
that favors differentiation of and energy storage by adipocytes.
[0009] Many of
the physiological processes in play in the development of undesirable
.. skin or hair have counterparts in eukaryotic microorganisms, such as yeast,
and yeasts
extracts have been used in cosmetic applications. For example, in response to
heat, UV
radiation, or other stress, yeast are known to produce factors that promote
cell proliferation or
viability. See, e.g., U.S. Pat. No. 2,239,345. Stressed yeast lysates
containing such factors
have been described and have been indicated for use in cosmetic applications
directed to
counteracting the effects of certain stresses on the skin. For example, UV-
stressed yeast
lysates have been used in cosmetic applications. See, e.g., U.S. Pat. Nos.
5,643,587;
5,676,956; and 5,776,441. More recently, ozone-stressed yeast lysates have
been described
as useful in protecting skin cells from the harmful effects of ozone. See,
e.g., U.S. Pat. Nos.
6,461,857 and 6,858,212 to Scholz et al; and U.S. Pat. Appl. Pub. Nos.
2003/0198682 and
2006/0110815. Nonetheless, these earlier cases failed to recognize certain
cosmetic uses and
failed to identify active ingredients within the cellular lysates.
[0010]
Accordingly, there remains a need for better-defined cosmetic compositions
that effectively provide additional skin benefits, including exfoliating, anti-
aging, anti-lipid,
anti-inflammatory, and/or skin (or hair) lightening effects. It is therefore
an object of the
invention to provide compositions and methods for decreasing melanin
synthesis, TNFa
production, PPARs signaling, and/or metalloproteinase activity; and/or for
increasing
collagen synthesis, hyaluronic acid production, and/or KLKs activity. It is a
further object of
3
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
the invention to improve overall appearance of skin and hair, and to lighten
the skin and hair
as desired, by use of such compositions.
[0011] The
foregoing discussion is presented solely to provide a better understanding
of the nature of the problems confronting the art and should not be construed
in any way as
an admission as to prior art nor should the citation of any reference herein
be construed as an
admission that such reference constitutes "prior art" to the instant
application.
SUMMARY OF THE INVENTION
[0012] In
accordance with the foregoing objectives and others, it has surprisingly
been found that specific peptide fractions derived from stressed yeast and
complexed with
metal ions are capable of decreasing melanin synthesis, TNFa production, PPARs
signaling
and/or collagen degradation, and/or increasing collagen synthesis, hyaluronic
acid
production, and/or KLKs activity; and thus are beneficial agents for improving
the
appearance of skin and hair. It has further surprisingly been found that
melanin synthesis is
decreased by inhibition of calcium influx into pigment cells, providing a
novel approach to
reducing hyper-pigmentation.
[0013] One
aspect of the instant invention relates to modified yeast peptide fractions
for use in cosmetic compositions. In particular, compositions comprising a
modified yeast
peptide fraction comprising a peptide comprising SEQ ID NO:1 are provided,
where the
peptide is complexed with metal ions, preferably divalent metal ions, such as
zinc ions. Such
compositions find use as anti-lipid, anti-inflammatory and/or skin lightening
agents, as well
as in enhancing exfoliation and/or treating and/or preventing visible signs of
skin aging. In
some embodiments, the modified peptide fraction is present in an amount
sufficient to
decrease at least one of melanin synthesis, TNFa production, and/or PPARs
signaling. In
some embodiments directed against signs of aging, the modified peptide
fraction is present in
an amount sufficient to decrease metalloproteinase activity; increase collagen
synthesis;
increase hyaluronic acid production, and/or increase KLKs activity.
[0014] Another
aspect of the instant invention relates to cosmetic use of compositions
comprising modified yeast peptide fractions comprising metal-complexed
peptides
comprising SEQ ID NO:1 to provide at least one benefit to human skin. Such
benefits
include:
(a) treatment and/or prevention of fine lines or wrinkles;
(b) reduction of skin pore size;
4
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
(c) improvement in skin thickness, plumpness, and/or tautness;
(d) improvement in skin suppleness and/or softness;
(e) improvement in skin tone, radiance, and/or clarity;
(f) improvement in skin texture and/or promotion of retexturization;
(g) improvement in skin barrier repair and/or function;
(h) improvement in appearance of skin contours;
(i) restoration of skin luster and/or brightness;
(j) replenishment of essential nutrients and/or constituents in the skin;
(k) improvement of skin appearance decreased by menopause;
(1) improvement in skin moisturization and/or hydration;
(m) increase in and/or preventing loss of skin elasticity and/or
resiliency;
(n) improvement in procollagen and/or collagen synthesis;
(o) treatment and/or prevention of skin sagging or atrophy;
(p) enhancing exfoliation and/or reducing dryneess;
(q) treatment and/or prevention of skin hyper-pigmentation;
(r) treatment and/or prevention of inflammation, such as redness, swelling,
and/or
puffiness;
(s) treatment and/or prevention of excess sebum output; and
(t) treatment and/or prevention of cellulite.
[0015] The compositions can be applied to skin in need of treatment, such
as skin that
would benefit from the exfoliating, anti-aging, anti-lipid, anti-inflammatory
and/or skin (or
hair) lightening effects of the compositions. In some embodiments, an
effective amount of
the modified yeast peptide fraction is provided in a cosmetically acceptable
vehicle and
topically applied to an area of skin for a time sufficient to produce the
desired effect.
Preferred topical formulations include a lotion, cream, ointment, essence,
gel, or stick. In
certain embodiments, the modified yeast peptide fraction is used to lighten
hair.
[0016] Still another aspect of the instant invention relates to the
use of calcium influx
inhibitors to treat hyper-pigmentation. The calcium influx inhibitors can
decrease melanin
synthesis by blocking calcium entry into pigment-producing cells. Preferred
calcium influx
inhibitors include modified yeast peptide fractions comprising peptides
comprising zinc-
complexed SEQ ID NO:1; and the compound 2-aminoethyl diphenylborate. In some
embodiments, an effective amount of a calcium influx inhibitor is provided in
a cosmetically
acceptable vehicle and topically applied to a hyper-pigmented area of skin, to
lighten the
5
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
affected area. In some embodiments, the inhibitor is combined with at least
one other skin
lightener. In some embodiments, the calcium inhibitor is used to lighten hair.
[0017] These
and other aspects of the invention will be better understood by reference
to the following detailed description of the invention.
DETAILED DESCRIPTION
[0018] It has
surprisingly been found that a modified yeast peptide fraction
comprising a peptide comprising metal-complexed SEQ ID NO:1 is capable of
decreasing
melanin synthesis by inhibiting calcium influx into pigment cells. It has
further surprisingly
been found that the modified yeast peptide fraction is capable of decreasing
TNFa
production, decreasing PPARs signaling, decreasing metalloproteinase activity,
increasing
collagen synthesis, increasing hyaluronic acid production, and/or increasing
KLKs activity.
[0019] In view
of these findings and others, a topical composition comprising a
modified yeast peptide fraction comprising a metal-complexed peptide
comprising SEQ ID
NO:1 is contemplated to be useful in lightening skin (or hair), reducing
inflammation,
enhancing exfoliation, and/or controlling lipid over-production, as well as in
combating signs
of skin damage and skin aging, including reducing fine lines and wrinkles,
preserving skin
firmness and plumpness, improving skin hydration and resiliency, restoring
skin luster and
brightness, and counteracting other related signs of skin aging. It is further
contemplated that
other compounds that inhibit calcium influx into pigment cells can find use in
lightening skin
and/or hair.
Modified Yeast Peptide Fractions and Metal-Complexed Peptides thereof
[0020] One
aspect of the instant invention relates to modified peptide fractions of
stressed yeast extracts. The fractions comprise peptides having the sequence
shown in SEQ
ID NO:1, where there peptides are in complexation with metal ions.
"Complexation with
metal ions," and related terms such as "metal complex", "metal-complexee,
"metal-
complexed derivative", "complex with metal ions", and the like, refer herein
to a
coordination compound of a central peptide connected to surrounding metal
ions. The metal
ion may be any metal cation capable of forming a complex with one or more
negatively-
charged amino acid residues of the peptide, including without limitation, ions
of alkali
metals, alkaline earth metals, transition metals, post-transition metals,
lanthanides, actinides,
metalloids, and the like, or any combination thereof. Typically, the metal ion
will be of the
form WI', where M is any metal or metalloid and n is an integer from 1 to 4,
typically 1 or 2.
6
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0021] As used
herein, "peptide" refers to any composition that includes two or more
amino acids joined together by a peptide bond. Peptides may be about 2 to
about 200 amino
acids or more in length, and generally correspond to a fragment of a full-
length protein,
where the fragment does not include all the amino acids of the native full-
length protein. In
some embodiments, the peptide may be from at least about 3, at least about 4,
at least about 5,
at least about 6, at least about 8, at least about 10, at least about 15, or
at least about 20 amino
acids in length. In some embodiments, the peptide may be no more than about
200, no more
than about 100, no more than about 50, no more than about 30, or no more than
about 20
amino acids in length. For example, in some preferred embodiments, the peptide
includes
less than about 20 amino acids, less than about 15 amino acids, less than
about 10 amino
acids, or about six amino acids, including the sequence Phe-Val-Ala-Pro-Phe-
Pro.
[0022] In some
embodiments, one or more of the six amino acids in the sequence
Ph e-Val - A l a-Pro-Ph e-Pro can be conservatively substituted. Suitable
conservative
substitutions of amino acids arc known to those of skill in this art and
generally can be made
without altering the biological activity of the resulting molecule. Amino acid
substitutions
are typically of single residues, but may be of multiple residues, either
clustered or dispersed
along the hexameric sequence. An amino acid can be replaced with a different
naturally-
occurring or a non-conventional amino acid residue. Such substitutions may be
classified as
"conservative," where an amino acid residue contained in the peptide is
replaced with another
amino acid of similar character either in relation to polarity, side chain
functionality, andior
size. Examples include substituting Phe with Met, Leu or Tyr; substituting Val
with Ile or
Leu; or substituting Ala with Gly or Ser.
[0023] It
further will be appreciated that peptides may contain amino acids other than
the 20 amino acids commonly referred to as the 20 naturally-occurring amino
acids, and that
many amino acids, including the terminal amino acids, may be modified in a
given peptide,
either by natural processes such as glycosylation and other post-translational
modifications,
or by chemical modification techniques, such as those well known in the art.
Among the
known modifications which may be present in peptides of the present invention
include, but
7
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
are not limited to, acetylation, acylation, ADP-ribosylation, amidation,
branching, cross-
linking, cyclization, disulfide bond formation, demethylation, glycosylation,
hydroxylation,
iodination, methylation, oxidation, phosphorylation, prenylation,
racemization, selenoylation,
sulfation, and ubiquitination.
[0024] In some embodiments, the peptide consists essentially of an amino
acid
sequence corresponding to SEQ ID NO:l. "Consists essentially of" means that
the peptide
excludes additional sequences and other compositional components that would
materially
affect the ability of the peptide to effectively decrease melanin synthesis,
TNFa production,
PPARs signaling, and/or collagen degradation, and/or increase collagen
synthesis, hyaluronic
.. acid production, and/or KLKs activity. The ability to affect such functions
can be determined
by one of ordinary skill in the art using, e.g., assays, such as in vitro
assays described herein
(see Examples 1-7 and 13 below) Or other assays known in the art to test for
melanin
synthesis, TNFa production, PPARs expression or signaling, collagen synthesis,
collagen
degradation, hyaluronic acid production, and/or KLKs activity.
[0025] The modified yeast peptide fractions of the instant invention can be
obtained
directly from certain yeasts, e.g., from Saccharomyces cerevesiae. For
example, the yeast
peptide fractions can be obtained from stressed yeast extracts, prepared by
growing yeast on
nutritional media, e.g., using standard fermentation processes known to those
skilled in the
art, subjecting the yeast to stress, and then lysing the cells. The growing
cells are subjected to
one or more stresses, generally at sub-lethal doses. Stresses include, e.g.,
heat, UV radiation,
x-rays, hydrogen peroxide, ozone, pollutants, chemical injury or other adverse
conditions. A
"stressed yeast" is a yeast that has undergone exposure to one or more such
stresses. A
"stressed yeast extract" is a lysate obtained from yeast grown on nutritional
media that were
at some point exposed to one or more stresses and subsequently killed to
provide a
composition comprising yeast components. "Yeast extract" refers to a lysate
obtained from
yeast grown on nutritional media and subsequently killed so as to provide a
composition
comprising yeast components including, but not limited to, cellular protein
material, cellular
nuclear material, cellular cytoplasmic material, cellular protoplasmic
material, cell wall
components, and/or the nutrient broth. The term "yeast" can encompass a single
yeast cell,
multiple yeast cells, and/or a culture of yeast cells.
[0026] The
yeast used may be of various genus known to those skilled in the art,
where it is determined that peptides comprising SEQ ID NO:1 are obtainable
therefrom.
Without wishing to be bound by theory, it is suggested that yeast respond to
stresses, such as
8
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
UV radiation, by generating cellular components, including proteins, which are
capable of
counteracting the detrimental effects of the stress, and which surprisingly
have been found to
also offer different and additional benefits to human skin cells, as taught
herein. Expression
of such proteins may be induced or up-regulated in response to the stress. The
induced or up-
regulated proteins include proteins have been termed yeast "heat shock
proteins" (lisp), also
called "stress response proteins." See, e.g., U.S. Pat. No. 2,239,345. Heat
shock proteins are
known to improve cell proliferation and/or cell viability in the face of
adverse conditions, for
example, by replacing cellular functions disabled by the stress, or by acting
as molecular
chaperones to protect native structures, such as by modifying protein folding.
[0027] For example, yeast proteins induced or up-regulated in response to
stress, such
as UV exposure, can be determined by comparing the proteins present in
stressed yeast
extracts to those present in extracts of yeast not subjected to the same
stress, using for
example comparative two-dimensional polyacrylamide gel electrophoresis. See,
e.g., U.S.
Pat. App. Publ. 2006/0110815. Another approach involves running a yeast gene
microarray
to identify yeast genes whose expression changes in response to the stress,
e.g., to determine
which genes are induced, up-regulated, turned off, or down-regulated in
response to the
stress. Such comparisons can indicate a number of yeast heat shock proteins
induced or up-
regulated in response to stress, and the identified proteins can be analyzed
to determine
whether or not they contain SEQ ID NO:1. Different yeasts that may be analyzed
include,
without limitation: Arthroascus, Aureobasidium, Botryoascus, Brettanomyces,
Candida,
Citeromyces, Clavispora, Cryptococcus, Debaryomyces, Dekkera, Filobasidium,
Guilliermondella, Hansenula, Han eseniaspora, Hormoascus, Klockera,
Kluyveromyces,
Leucosporidium, Lipomyces, Malassezia, Metschnikowia, Nadsonia, Nematospora,
Oosporidium, Pachysolen, Pachytichospora, Pichia,
Prototheca,
Rhodosporidium, Rho dotorula, Saccharomyces, Saccharomycodes,
Saccharomycopsis,
Schizosuccharomyce, Schvvanniornyce,s, Sporobolomyces, Sporopuchydermia,
Tremella,
Trichosporan, Trigonopsis, Torulaspora, Torulopsis, Williopsis, Yarrowia,
Zygosaccharomyces and the like, and any of those found to produce proteins or
peptides
comprising SEQ ID NO:1 may be used, as well as combinations thereof SEQ ID
NO:1 has
also been found in transmembrane proteins of Saccharomyces cerevisiae and may
also occur
in the transmembrane proteins of one or more other species, such as one or
more of the other
yeast species listed above.
9
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0028] In some
embodiments, the yeast used is from the genus Saccharomyces. In
certain preferred embodiments, the yeast is Saccharomyces cerevisiae, also
known as Baker's
yeast. Also, certain types of yeasts may be excluded in some embodiments. For
example, in
some embodiments, the yeast used in not a wine yeast (e.g., as described in
French Patent No.
FR 2904552 and Japanese Patent No. JP 2003252743) and/or not Candida
parapsilosis (e.g.,
as described in Korean Patent No. KR 2005095167).
[0029] The
selected one or more species of yeast can be grown at a controlled
temperature on nutritional media, which is also referred to as nutrient media
or growth media.
Typically the media contains amino acids, peptones, low molecular weight
peptide fragments,
and other common growth media ingredients. A preferred growth media is "yeast
fermentation media," which is described in the Handbook of Microbiological
Media,
published by CRC Press. Methods for growing yeast are known to those skilled
in the art.
For example, the yeast can be grown in an open-air fermentation vessel, or by
using a sealed
biological fermentor, e.g., available from New Brunswick Scientific, Edison,
N.J. At some
point, the growing cells are subjected to one or more stresses, generally at
sub-lethal doses.
Stresses include, e.g., heat, UV radiation, x-rays, hydrogen peroxide, ozone,
pollutants,
chemical injury or other adverse conditions. Typically, the stress is used in
an amount to
cause a response in the yeast, e.g., to induce production of heat shock
proteins, yet that is sub-
lethal to the yeast. By sub-lethal it is meant that at least about 1% of the
yeast survive after
.. exposure to the stress. In some embodiments, at least about 1%, at least
about 10%, at least
about 25%, at least about 50%, or at least about 80% of the yeast to survive
the treatment.
[0030] In some
preferred embodiments, the living yeast cells are stressed with UV
light, more preferably at 286 nm. As discussed above, the cells respond by
producing various
protective substances. The cells' biochemical changes can be monitored, for
example, by
.. assaying absorption at 256 to 258 nm with a UV spectrophotometer. The
degree of UV
exposure can affect which proteins, including heat shock proteins, are
produced, and the
amounts thereof The yeast may be exposed to the UV for several minutes to
several days,
depending on yeast type, wavelength used, aeration rates, temperature, and the
like.
Generally, exposure to UV light is continued for up to several days, until the
complex
biochemical protective mechanism is complete.
[0031] In some
embodiments, the yeast are exposed to wavelength(s) of UV
radiation for a time period that allows a maximum, near maximum, or
appreciable portion of
the yeast to produce cellular components effective in providing a benefit to
human skin or
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
hair, e.g., in improving the appearance of skin or hair. In certain preferred
embodiments, the
yeast are exposed to wavelength(s) of UV radiation for a time period that
allows a maximum,
near maximum, or appreciable portion of the yeast to produce cellular
components effective
against unwanted skin conditions, including hyper-pigmentation, inflammation,
lipid over-
.. production, and/or visible signs of aging. For example, the yeast can be
exposed to
wavelength(s) of UV radiation for a time period that allows a maximum, near
maximum, or
appreciable portion of the yeast to produce cellular components capable of
decreasing one or
more of melanin synthesis, TNFa production, PPARs signaling, and
metalloproteinase
activity; and/or increasing collagen synthesis, hyaluronic acid production,
and/or KLKs
activity. In certain preferred embodiments, the yeast are exposed to
wavelength(s) of UV
radiation for a time period that allows a maximum, near maximum, or
appreciable portion of
the yeast to produce at least one heat shock protein, more preferably where
the heat shock
protein(s) include at least one peptide portion capable of decreasing one or
more of melanin
synthesis, TNFa production, PPARs signaling, and metalloproteinase activity;
and/or
increasing one or more of collagen synthesis, hyaluronic acid production, and
KLKs activity.
In certain particularly preferred embodiments, the yeast are exposed to
wavelength(s) of UV
radiation for a time period that allows a maximum, near maximum, or
appreciable portion of
the yeast to produce heat shock proteins that include a peptide comprising SEQ
ID NO: 1
(Phe- V al-Ala-Pro-Phe-Pro).
[0032] The stressed yeast then can be lysed to obtain a stressed yeast
extract, for
example, fermentation can be brought to a halt by breaking down cell walls
with a suitable
proteolytic enzyme. The yeast can be lysed by a variety of methods known to
one skilled in
the art, including but not limited to, enzymes, high-speed agitation,
autolysis, changes in
growth media, and/or changes in pH. The stressed yeast extract typically
contains water-
soluble and water-insoluble components. The water-insoluble components may be
separated
and removed to provide stressed yeast extracts that comprise water-soluble
components. For
example, the insoluble cell wall material can be separated with centrifuge and
cellular
protoplasm harvested. In some embodiments, the yeast extract is water-soluble,
or
substantially water-soluble. "Water-soluble" typically means that 0.1 gram of
yeast
components dissolve in 1 gram of water.
[0033] The
stressed yeast extracts may be further purified, as desired, by any number
of means known to those skilled in the art including, but not limited to,
chromatography,
steam distillation, solvent extraction, centrifugation, decantation,
filtration, and/or carbon
11
treatment. The stressed yeast extracts can be purified and/or concentrated to
give fractions
suitable for cosmetic use.
A "fraction" as used herein refers to a
portion of a yeast extract obtained by at least one purification, separation,
and/or
concentration procedure. A "peptide fraction" refers to a portion of a yeast
extract that has
been separated, purified, and/or concentrated to increase yeast peptide
components of a yeast
extract. As known to those of skill in the art, the fraction can be tested to
determine its
suitability for cosmetic use.
[0034] In certain preferred embodiments, the extract is fractionated
using
centrifugation, filtration and/or chromatography systems to isolate a dominant
peptide
fraction. The stressed yeast extract can be purified to enrich small molecular
weight peptides,
within a 1000 to 3000 Da range, wherein peptides comprising the hexameric
peptide Phe-
Val-Ala-Pro-Phe-Pro is the dominant fraction. The peptides can be
substantially isolated
from other components of the stressed yeast extract, and preferably include
less than the full-
length proteins from which they are derived.
[0035] In some embodiments, the hexameric peptide itself is
synthesized, e.g., using
automated chemical synthesis or recombinant means, and re-added to the yeast
peptide
fraction, e.g,, to artificially increase the concentration of the hexameric
peptide in the yeast
peptide fraction. For example, the relatively short molecules may be
synthesized using
standard chemical peptide synthesis as a single contiguous peptide. Solid
phase synthesis can
be used, in which the C-terminal amino acid of the sequence is attached to an
insoluble
support followed by sequential addition of the remaining amino acids in the
sequence.
Techniques for solid phase synthesis are described, e.g., by Barany and
Merrifield, Solid-
Phase Peptide Synthesis; pp. 3 284; in The Peptides: Analysis, Synthesis,
Biology. Vol. 2:
Special Methods in Peptide Synthesis, Part A.; in Merrifield, et al. (1963) J.
Am. Chem. Soc.,
85: 2149 2156; and in Stewart ct al. (1984) Solid Phase Peptide Synthesis, 2nd
ed. Pierce
Chem. Co., Rockford, Ill.
12
CA 2768653 2017-08-30
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0036] The
hexameric peptide also can be synthesized using recombinant expression
systems. Generally, this involves creating a DNA sequence that encodes the
desired peptide,
placing the DNA in an expression cassette under the control of a particular
promoter,
expressing the peptide in a host, isolating the expressed peptide and, if
required, renaturing
the peptide. See, e.g., U.S. Patent No. 7,030,231. DNA encoding peptides
comprising SEQ
ID NO:1 can be prepared by any suitable method including, for example, cloning
and
restriction of appropriate sequences or direct chemical synthesis by methods
such as the
phosphotriester method of Narang et al. (1979) Meth. Enzymol. 68: 90 99; the
phosphodiester
method of Brown et al. (1979) Meth. Enzymol. 68: 109 151; the
diethylphosphoramidite
method of Beaucage et al. (1981) Tetra. Lett., 22: 1859 1862; and the solid
support method of
U.S. Pat. No. 4,458,066. Chemical synthesis may produce a single stranded
oligonucleotide,
which may be converted into double-stranded DNA by hybridization with a
complementary
sequence or by polymerization with a DNA polymerase using the single strand as
a template.
[0037]
Alternatively, sequences may be cloned and the appropriate subsequences
cleaved using appropriate restriction enzymes. The nucleic acid sequence
encoding the
hexameric peptide can then be ligated into a vector having the appropriate
corresponding
restriction sites. Appropriate restriction sites can also be added to the
nucleic acid encoding
the peptide by site-directed mutagenesis. The sequence may be expressed in a
variety of host
cells, including yeast, E. coli, other bacterial hosts, and various higher
cukaryotic cells such
as the COS, CHO and HeLa cells lines, as well as myeloma cell lines. The
recombinant
sequence will be operably linked to appropriate expression control sequences
for each host.
One of skill would recognize that modifications can be made to peptides
without diminishing
their biological activity. Some modifications may be made to facilitate the
cloning or
expression of the molecule. Such modifications are well known to those of
skill in the art and
include, for example, a methionine added at the amino terminus to provide an
initiation site,
or additional amino acids (e.g., poly His) placed on either terminus to create
conveniently
located restriction sites or termination codons or purification sequences.
[0038]
Expression vectors can be transferred into the chosen host cell by well-known
methods, such as calcium chloride transformation for E. coil and calcium
phosphate treatment
or electroporation for mammalian cells. Cells transformed by the plasmids can
be selected by
resistance to antibiotics conferred by genes contained on the expression
vectors, such as the
amp, gpt, neo and hyg genes. Once expressed, the recombinant peptide(s) can be
purified
according to standard procedures of the art, including ammonium sulfate
precipitation,
13
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
affinity columns, column chromatography, gel electrophoresis and the like.
See, generally,
R. Scopes, (1982) Protein Purification, Springer-Verlag, N.Y.; Deutscher
(1990) Methods in
Enzymology Vol. 182: Guide to Protein Purification., Academic Press, Inc. N.Y.
The peptide
can be purified and/or concentrated to give a form suitable for cosmetic use.
As known to
those of skill in the art, the peptide composition can be tested to determine
its suitability for
cosmetic use, as discussed above. The synthesized peptides comprising SEQ ID
NO:1 can
then be added to an isolated yeast peptide fraction, as described above. The
hexameric
peptide as well as yeast peptide fractions comprising the peptide as a
dominant fraction are
also available commercially, e.g., Peptamide 6 (INCI name Hexapeptide 11),
available
from Arch Personal Care Products, L.P., South Plainfield, NJ
(www.archpersonalcare.com).
[0039] The
yeast peptide fractions can then be modified by complexation with one or
more metal ions to give modified yeast peptide fractions. As used herein
"modified yeast
peptide fraction," along with related terms such as "modified peptide
fraction," are used
herein to refer to a peptide fraction of a yeast extract that contains one or
more metal-
complexed peptides, that is at least one peptide complexed with metal ions.
For example, the
yeast peptide fraction may be washed with an aqueous metal salt solution to
form complexes
between the metal ions and one or more peptides in the fraction. The metal
salt may
comprise, without limitation, salts of alkali metals, alkaline earth metals,
transition metals,
post-transition metals, lanthanides, actinides, metalloids, and the like, or
any combination
thereof. In certain preferred embodiments, the metal salt is a divalent metal
salt, such as that
of calcium (Ca2+), Copper (Cu2+), magnesium (Mg2+), manganese (Mn2'),
beryllium (Be2'),
zinc (Zn2'), and the like; and the salts may include sulfates, bromides,
chlorides, phosphates,
acetates, and the like. Some particularly preferred embodiments use zinc
salts, such as, e.g.,
zinc bromide, zinc chloride, zinc phosphate, zinc acetate, zinc sulfate, and
the like. For
example, the yeast peptide fraction may be washed with an aqueous zinc sulfate
solution,
even more preferably a saturated aqueous zinc sulfate solution, to form zinc
complexes with
the peptides, including a zinc complex with the peptide comprising SEQ ID
NO:l.
[0040] After
the reaction has proceeded to completion, residual anions and free metal
ions, if any, can be removed by ion exchange column chromatography. That is,
the metal-
complexes formed can be run on an ion exchange column to remove, e.g., excess
uncomplexed ions. This can provide metal-complexed peptides that are free,
substantially
free, or even completely free of metal salts and free metal ions. The
resulting composition is
a modified peptide fraction of the yeast extract, the modification being the
complexation with
14
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
added metal. The metal-complexed peptide comprising SEQ ID NO:1 may constitute
from
about 0.001 weight % to about 5 weight %; preferably from about 0.01 weight %
to about 3
weight %; and more preferably from about 0.1 weight % to about 2 weight %, or
about 0.1
weight %, based on the total weight of this modified peptide fraction of the
yeast extract.
Other remaining components of the modified yeast peptide fraction may include,
e.g., other
low molecular weight peptides, oligopcptides, sugar, and oligosachharidcs.
Based on the
teachings herein, other approaches will be apparent to those of skill in the
art for generating
modified yeast peptide fractions comprising metal-complexed peptides
comprising SEQ ID
NO:1 from suitable yeast peptide fractions.
[0041] Cosmetic compositions of the instant invention generally comprise an
amount
of modified yeast peptide fraction comprising a metal-complexed peptide
comprising SEQ ID
NO:1 effective to provide a benefit to human skin. In preferred embodiments,
the
compositions comprise an amount of modified peptide fraction, and/or an amount
of metal-
complexed peptide comprising SEQ ID NO:1, effective to decrease melanin
synthesis, TNFa
.. production, PPARs signaling, and/or metalloproteinase activity; and/or to
increase collagen
synthesis, hyaluronic acid production, and/or KLKs activity. In
certain preferred
embodiments, the cosmetic composition comprises an amount of metal-complexed
peptide
comprising SEQ ID NO:1 from about 0.001 weight % to about 5 weight % based on
the total
weight of the composition; preferably from about 0.01 weight % to about 3
weight % based
on the total weight of the composition; and more preferably from about 0.1
weight % to about
2 weight %, or about 1 weight %, based on the total weight of the composition.
The above
amounts refer to an "active amount" of the modified yeast peptide fraction,
such as the
amount of metal-complexed peptide comprising SEQ ID NO:1. The term "active
amount"
refers to the amount of modified peptide fraction and/or metal-complex peptide
comprising
.. SEQ ID NO:1, absent diluent, solvent, carrier, filler or the like. Cosmetic
compositions
described herein find use as exfoliating, anti-aging, anti-lipid, anti-
inflammatory, and/or skin
(or hair) lightening agents, e.g., as detailed below.
Cosmetic Use of Modified Yeast Peptide Fractions and Related Compositions
[0042] Another
aspect of the instant invention relates to cosmetic use of compositions
comprising modified yeast peptide fractions comprising a metal-complexed
peptide
comprising SEQ ID NO:1; and/or other calcium influx inhibitors. The
cosmetic
compositions surprisingly act to increase one or more of KLKs activity,
hyaluronic acid
production, and collagen synthesis; and/or to decrease one or more of
metallocollagenase
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
activity, PPARs signaling, TNFa production, and melanin synthesis, and
accordingly find use
in exfoliating, anti-aging, anti-lipid, anti-inflammatory, and/or skin (or
hair) lightening
products.
[0043] In some embodiments, a method for providing at least one
benefit to human
skin is provided, where the method comprises topically applying to skin in
need thereof at
least one composition described herein in a cosmetically acceptable vehicle.
The
composition will comprise an effective amount of a modified yeast peptide
fraction; metal-
complexed peptide comprising SEQ ID NO:1; and/or other calcium influx
inhibitor. An
"amount effective" or an "effective amount" to provide a particular benefit to
the skin refers
to the active amount of modified fraction, metal-complexed peptide, or calcium
influx
inhibitor sufficient to provide a clinically measurable improvement in the
particular
manifestation of skin when applied for a sufficient time. Such benefits
include without
limitation, the following:
(a) treatment and/or prevention of fine lines or wrinkles;
(b) reduction of skin pore size;
(c) improvement in skin thickness, plumpness, and/or tautness;
(d) improvement in skin suppleness and/or softness;
(e) improvement in skin tone, radiance, and/or clarity;
(f) improvement in skin texture and/or promotion of retexturization;
(g) improvement in skin barrier repair and/or function;
(h) improvement in appearance of skin contours;
(i) restoration of skin luster and/or brightness;
replenishment of essential nutrients and/or constituents in the skin;
(k) improvement of skin appearance decreased by menopause;
(1) improvement in skin moisturization and/or hydration;
(m) increase in and/or preventing loss of skin elasticity and/or
resiliency;
(n) improvement in procollagen and/or collagen synthesis;
(o) treatment and/or prevention of skin sagging or atrophy;
(p) enhancing exfoliation and/or reducing dryness;
(q) treatment and/or prevention of skin hyper-pigmentation;
(r) treatment and/or prevention of inflammation;
(s) treatment and/or prevention of excess sebum output; and
(t) treatment and/or prevention of cellulite.
16
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0044] The
compositions of the invention can be applied to skin in need of treatment,
such as skin which suffers from a deficiency or loss in any of the foregoing
attributes or
conditions, or which would otherwise benefit from the composition's
exfoliating, anti-aging,
anti-lipid, anti-inflammatory and/or skin lightening effects, e.g., as
described herein. For
example, the modified peptide fraction comprising a metal-complexed peptide
comprising
SEQ ID NO:1 and/or other calcium influx inhibitor can be provided in a
cosmetically
acceptable vehicle, topically applied to a desired area of skin, and allowed
to remain on the
area in an amount effective to treat and/or prevent an unwanted feature or
condition of the
skin, and/or to improve the aesthetic appearance of the skin. For example,
exfoliating
.. benefits may be realized within minutes, while other benefits may require
longer periods of
time on the skin.
[0045]
"Condition of the skin" or "skin condition" is used interchangeably herein
with "skin disorder." "Treatment" as used herein, as well as related terms
such as "treat" or
"treating," refers to eradicating, reducing, ameliorating, or reversing one or
more of the
.. unwanted features associated with the skin condition being treated, such
that the consumer
perceives an improvement or other treatment benefit with respect to the
condition.
"Prevention" as used herein, as well as related terms such as "prevent" or
"preventing," refers
to affording skin not yet affected by the condition a benefit that serves to
avoid, delay,
forestall, or minimize one or more unwanted features associated with the skin
condition to be
prevented. Such preventative benefits include, for example, delaying
development of the
condition, or reducing the duration, severity, or intensity of one or more
unwanted features
associated with the condition if it eventually develops.
Hyper-pigmentation
[0046] In
certain preferred embodiments, the cosmetic compositions described herein
can be used to treat and/or prevent hyper-pigmentation of skin and/or that of
the hair, for
example, to lighten skin or hair. In some particularly preferred embodiments,
a composition
comprising an effective amount of a modified yeast peptide fraction peptide
comprising a
metal-complexed peptide comprising SEQ ID NO:1 is topically applied to the
skin or hair,
for example to an area of hyper-pigmented skin or hair. "Hyper-pigmentation"
as used herein
and unless otherwise specifically indicated, refers to "melanocyte-mediated
hyper-
pigmentation," meaning that the coloration is exclusively, mostly, or at least
substantially
caused by the action of melanocytes, pigment-producing cells that synthesize
melanin.
17
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0047] Hyper-
pigmentation includes any coloration of an individual's skin or hair that
is darker than desired by the individual and that is caused by melanocytes.
Such unwanted
pigmentation may also be called discoloration. Hyper-pigmented areas of the
skin include
areas of discrete or mottled hyper-pigmentation. Areas of discrete hyper-
pigmentation can be
distinct, uniform areas of darker color and may appear as brown spots or
freckles on the skin,
including marks commonly called pigment spots or "age spots." Areas of mottled
hyper-
pigmentation of the skin can be dark blotches that are larger and more
irregular in size and
shape than areas of discrete pigmentation. Areas of hyper-pigmentation also
include areas of
tanned skin, e.g., skin tanned due to UV exposure. Hyper-pigmented hair
includes any shade
of hair that is darker than desired.
[0048] Skin
hyper-pigmentation may be caused by any number of factors, including,
for example, genetics, UV or sun exposure, age, scarring, or discoloration due
to skin injury,
including lacerations, burns, sunburn, acne, or other dermatological
conditions, and the like.
For example, skin hyper-pigmented areas include melasmic patches. Melasma is a
common
skin disorder involving facial skin discoloration, particularly prevalent in
pregnant women,
where it is called chloasma faciei or chloasma. Melasmic (or chloasmic)
patches may appear
as dark brown, irregular patches on the face, particularly on the upper
cheeks, nose, lips,
upper lip, and forehead. The patches often develop gradually over time and
generally do not
itch or otherwise hurt, but may negatively affect an individual's appearance.
Skin hyper-
pigmentation also refers to areas under the arm, e.g., that have become or are
becoming
darker than desired.
[0049] Skin
hyper-pigmentation may or may not include areas under an individual's
eyes that are darker than desired by the individual, commonly referred to as
"under eye dark
circles" or "dark circles." Dark circles are usually round, uniform areas of
pigmentation
beneath each eye, which may be caused by heredity, allergies, tiredness, or
other causes.
Treatment of hyper-pigmentation, in some embodiments, excludes treating
discoloration
and/or bagginess in facial skin below the eyes. Notably, under-eye hyper-
pigmentation is not
a simple melanocyte-mediated pigmentation problem. See, e.g., U.S. Pat. No.
5,643,587.
Etiologies include circulatory malfunctions, such as increased vascular
permeability causing
leakage beneath the skin surface, inflammation, and exposure to the
environment, and the
problem generally does not respond well to known hypo-pigmenting or skin
whitening
compounds. Indeed, the topical composition used to reduce under-eye
discoloration in that
case included a high percentage of ascorbyl phosphate, which itself is a known
skin lightener
18
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
and thus may have been responsible for the under-eye skin lightening. Example
14 below
further confirms that the stressed yeast extracts described in U.S. Pat. No.
5,643,587, do not
act to reduce under-eye hyper-pigmentation, in the absence of ascorbyl
phosphate and in the
absence of metal-complexed peptides of the instant invention.
[0050] Treating
hyper-pigmentation or hyper-pigmented skin/hair refers to
eradicating, reducing, ameliorating, or reversing one or more of the unwanted
features
associated with hyper-pigmentation, such as producing a perceptible lightening
of the skin or
hair in the affected area. Lightening hyper-pigmented areas of the skin may be
desirable, in
particular, in diminishing age spots; lightening a suntan; evening or
optimizing skin tones,
e.g., in areas of mottled hyper-pigmentation; in treating melasmic and
chloasmic patches,
freckles, after-burn scars, and post-injury hyper-pigmentation.
Preventing hyper-
pigmentation or hyper-pigmented skin refers to affording skin, not yet
affected by hyper-
pigmentation, a benefit that serves to avoid, delay, forestall, or minimize
one or more
unwanted features associated with skin hyper-pigmentation, such as reducing
the darkness or
size of hyper-pigmented areas that eventually develop. Modified yeast peptide
fractions
comprising metal-complexed peptides comprising SEQ ID NO:1 that are capable of
treating
and/or preventing hyper-pigmented skin can be referred to as "skin
lighteners." When used
for lightening hair, they can be referred to "hair lighteners." "Lightening"
and related terms
refer to any process making undesirably dark areas lighter, and includes the
concepts of
bleaching, hypo-pigmenting, whitening and/or de-pigmenting. Compositions used
in hyper-
pigmentation applications will comprise an effective amount of modified yeast
peptide
fraction, and/or metal-complexed peptide(s) comprising SEQ ID NO:1, to treat
and/or
prevent hyper-pigmentation, such as, e.g., to lighten skin/hair in an affected
area.
[0051]
Pigmentation of the skin (including the lips) and hair is determined by the
level and type of melanin present in the epidermis or hair fiber. For example,
the greater the
epidermal level of DHI-melanin, the darkest type of melanin, the darker the
skin. As noted
above, melanin is synthesized in specialized organelles called melanosomes
within pigment
cells (also called pigment-producing cells or melanocytes), and the process
begins with the
conversion of the amino acid tyrosine to dopaquinone by the enzyme tyrosinase.
Most other
skin lightening approaches have relied upon tyrosinase inhibitors applied to
the skin to
decrease melanin synthesis. See, e.g., Korean Patent No. KR 2005095167; and
Japanese
Patent Nos. JP 2003252743, and JP 61260009. These cases, however, as well as
Japanese
Patent Nos. JP 2002234828 and JP 2001151631, used extracts obtained from non-
stressed
19
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
yeast, that is, from yeast that had not been exposed to one or more stresses.
Without wishing
to be bound by theory, it is believed that the modified peptide fractions
comprising metal-
complexed peptides comprising SEQ ID NO:1 do not rely upon a tryrosine
inhibitor to
decrease melanin synthesis, but appear to have a different mechanism of
action. Indeed, it
has been surprisingly found that compositions of the instant invention
decrease melanin
synthesis by inhibiting calcium influx into pigment cells. Furthermore, it has
been
surprisingly found that compositions comprising other calcium influx
inhibitors also can be
used in cosmetic applications against hyper-pigmentation. See Example 1 below.
[0052]
Accordingly, another aspect of the instant invention relates to cosmetic use
of
compositions comprising a calcium influx inhibitor for skin and/or hair
lightening. A
"calcium influx inhibitor" as used herein refers to any compound that acts to
decrease,
reduce, block, or otherwise inhibit the entry of calcium into pigment cells.
The term is used
interchangeably herein with "calcium channel inhibitor." Calcium influx
inhibitors will
include compounds known in the art to regulate calcium entry into pigment
cells, such as,
without limitation, 2¨aminoethyl diphenylborate (2-APB). For example, this
compound is
known to specifically block calcium entry into cells, including into pigment
cells. Other
known calcium influx inhibitors include, without limitation,
Aminohexahydrofluorene,
Bepridil, Calcicludine, Calciseptine, Calmidazolium chloride, Nifedipine,
Verapamil, FS2
(Dendroaspis polylepis polylepis), Galanin, Protopinc, Tetrahydropalmatine,
Somatostatin-
14, L-Stepholidinealverine and its salts; as well as manganese and its salts,
magnesium and it
salts. See, e.g., EP 1419764; Int. Pat. Appl. Pub. No. WO 2006048671; and U.S.
Pat. Appl.
Pub. No. 2009/0028826. Cosmetic compositions comprising calcium influx
inhibitors
surprisingly act to decrease melanin synthesis, and accordingly find use in
skin or hair
lightening products, e.g., for treating and/or preventing skin hyper-
pigmentation, or bleaching
hair. Calcium influx inhibitors that are capable of treating and/or preventing
hyper-
pigmented skin also can be referred to as "skin lighteners." When used for
lightening hair,
they also can be referred to "hair lighteners." Compositions used in hyper-
pigmentation
applications will comprise an effective amount of one or more calcium influx
inhibitors to
treat and/or prevent hyper-pigmentation, such as, e.g., to lighten skin/hair
in an affected area.
[0053] In certain embodiments, compositions of the instant invention
comprise a
modified peptide fraction comprising a metal-complexed peptide comprising SEQ
ID NO:1,
and/or other calcium influx inhibitor, in an amount sufficient to decrease
melanin synthesis in
a given area of skin (or hair) when topically applied thereto. As used herein,
"decreasing
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
melanin synthesis" and related expressions refer to reducing the amount of one
or more of the
different types of melanin biosynthesized in skin and/or deposited in hair,
and in particular
refers to reducing melanocyte-mediated hyper-pigmentation. Without wishing to
be bound
by theory, the decrease in melanin is believed to be caused by an inhibition
of calcium influx
into pigment cells, as noted above. Preferably, the decrease in melanin
synthesis results in
perceptible lightening of the skin (or hair) receiving treatment, although
some melanin
biosynthesis persists (and some calcium influx persists). For example, in some
embodiments,
melanin synthesis is reduced by at least about 10%, at least about 25%, at
least about 50%, at
least about 75%, or at least about 90%, compared to melanin synthesis in the
absence of a
composition comprising a skin (or hair) lightener. In some embodiments,
calcium influx is
reduced by at least about 20%, at least about 40%, at least about 50%, at
least about 80%, or
at least about 95%, compared to calcium influx in the absence of a composition
comprising
the skin (or hair) lightener. The extent of melanin synthesis and/or calcium
influx can be
determined by appropriate assays, e.g., in vitro assays described herein or
known in the art.
.. For example, Examples 1 and 13 below provide experimental details of assays
for
determining calcium influx inhibition and total melanin synthesis.
[0054] In some
embodiments, the cosmetic compositions for treating and/or
preventing hyper-pigmentation, e.g., lightening skin (or hair), further
comprise at least one
other skin lightener (or at least one other hair lightener). For example, the
cosmetic
composition comprising a modified peptide comprising a metal-complexed peptide
comprising SEQ ID NO:1, and/or other calcium influx inhibitor, in an amount
effective to
treat and/or prevent hyper-pigmentation may further comprise at least one
other skin lightener
(or at least one other hair lightener). For example, a tyrosine inhibitor,
including any of the
tyrosine inhibitors disclosed in KR 2005095167; JP 2003252743 and JP 61260009,
may be
included, in some embodiments. Any other substances that can be applied to the
skin (or
hair) to lighten the skin (or hair) may also be used as an additional skin (or
hair) lightener
with the compositions described herein. Examples of skin lighteners include,
without
limitation, hydroquinone, kojic acid, licorice and/or its derivatives,
ascorbic acid and/or its
derivatives, arbutin, bearbeffy extract, Glycyrrhiza glabra and its
derivatives, Chlorella
vulgaris extract, perilla extract, coconut fruit extract, and/or other
depigmenting agents.
Perilla extract is disclosed as a whitening agent, e.g., in U.S. Pat. No.
5,980,904 and Japanese
Publications Nos. 07025742, 07187989, 10265322, 2001163759, and 2001181173.
Coconut
fruit extract is disclosed as a whitening agent in Japanese Patent No.
2896815B2.
21
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0055] Other
skin lighteners include extracts of Butea frondosa, Naringi crenulata,
Stenoloma chusana, Azadirachta indica, Glycyffhiza glabra linn., Morinda
citrifolia, tomato
glycolipid, or any combinations thereof, as well as, ascorbyl glucoside,
vitamin C, retinol
and/or its derivatives, arbutin, rumex crispus extract, milk proteins
including hydrolyzed milk
.. proteins, N,N,S-tris(carboxymethyl)cysteamine, oleanolic acids, perilla
oils, placenta extract,
saxifragia sarmentosa, juniperic acid, thiodipropionic acid (TDPA), ligusticum
chiangxiong
hort., asmunda japonica thunb., stellaria medica (L.) cyr., sedum sarmentosum
bunge,
ligusticum lucidum Ait., ilex purpurea hassk, emblica, apigenin, ascorbyl
palmitol, carruba
polyphenols, hesperitin, inabata polyphenol, isoliquirtigenin, kaempherol-7-
neohesperidose,
.. L-mimosine, luteolin, oil-soluble licorice extract P-T(40), oxa acid,
phenyl isothiocyanate,
cococin, silymarin, T4CA, teterahydro curcumin, unitrienol, ursolic-oleanolic
acid,
UVA/URSI, or any combinations thereof Further, it is contemplated that
synergistic
improvements may be obtained with combinations of one or more such additional
skin (or
hair) lighteners with compositions of the instant invention, in some
embodiments. For
example, in some embodiments, the invention relates to synergistic action of
one or more
compositions described herein with TDPA, e.g., to provide enhanced skin
lightening benefits
to skin.
Inflammation
[0056] In
certain preferred embodiments, the cosmetic compositions described herein
.. can be used to treat and/or prevent inflammation, for example, to reduce
redness and/or
puffiness associated with inflammation of the skin. In some particularly
preferred
embodiments, a composition comprising an effective amount of a modified yeast
peptide
fraction comprising a metal-complcxed peptide comprising SEQ ID NO:1 is
topically applied
to the skin, for example to an area of inflamed skin. Inflammation generally
is caused by an
individual's response to unwanted stimuli, such as, for example, pathogens,
toxins, air
pollution, physical injury that damages cells, foreign bodies, such as a
splinter, burns,
chemical irritants, auto-immune reactions, and the like, and may be acute or
chronic. Stimuli
that produce an inflammatory response in an individual can be referred to as
"irritants."
Inflammation is generally characterized by five cardinal signs: redness,
increased heat,
.. swelling, pain, and loss of function. "Inflamed skin" or an "area of skin
affected by
inflammation" refers to any skin displaying one or more signs or features
associated with
inflammation, such as redness, swelling, or puffiness. Inflammatory skin
conditions include,
without limitation, eczema, edema, occupational dermatitis or contact
dermatitis, psoriasis,
22
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
acne, hives (also known as urticaria), rosacea, or other rashes or allergic
reactions in response
to irritants, such as poison ivy. Areas of inflammation include areas of the
skin affected by
such conditions, such as acne lesions, warts, pimples, blotches, and irritated
areas, such as
areas of redness, swelling, and/or puffiness, as well as areas of scaling,
flaking, itching,
burning, stinging, tingling, and/or numbing.
[0057] Treating
inflammation or inflamed skin refers to eradicating, reducing,
ameliorating, or reversing one or more of the unwanted features associated
with
inflammation, such as perceptibly reducing redness, puffiness, and/or swelling
of the affected
area, or soothing or calming the area. Preventing inflammation refers to
affording not yet
inflamed skin, a benefit that serves to avoid, delay, forestall, or minimize
one or more
unwanted features associated with inflammation, such as reducing the extent of
swelling that
may develop upon exposure to an irritant. Modified yeast peptide fractions
comprising
metal-complexed peptide comprising SEQ ID NO:1 that are capable of treating
and/or
preventing inflamed skin can be referred to as "anti-inflammatory agents."
Compositions
used against inflammation will comprise an effective amount of modified yeast
peptide
fraction, and/or metal-complexed peptide(s) comprising SEQ ID NO:1, to treat
and/or
prevent inflammation, such as, e.g., to reduce redness, swelling and/or
puffiness of an
affected area. In some particular embodiments, methods and compositions of the
instant
invention are directed to fighting all stages of the acne cycle - before,
during, and after a
breakout, e.g., preventing acne lesion before they surface, reducing the
number of acne
lesions that surface, accelerating healing during a breakout, etc.
[0058] A key
inflammatory mediator involved in inflammation is the cytokine tumor
necrosis factor-alpha (TNFa), also known as cachexin, or cachcctin. TNFa is
believed to be
responsible for both acute skin inflammation and chronic inflammation. TNFa is
produced
mainly by macrophages, as well as other cell types, including lymphoid cells,
mast cells,
endothelial cells, and fibroblasts, and a local increase in TNFa concentration
brings about the
cardinal signs of inflammation. Without wishing to be bound by theory, it is
believed that
modified yeast peptide fractions comprising metal-complexed peptides
comprising SEQ ID
NO:1 can act to decrease TNFa production, thereby reducing one or more of the
unwanted
features associated with inflammation, such as redness, puffiness, and/or
swelling. See
Example 2 below.
[0059] In
certain embodiments, the compositions of the instant invention comprise
modified yeast peptide fraction and/or metal-complexed peptide comprising SEQ
ID NO:1 in
23
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
an amount sufficient to decrease TNFa production in a given area of skin when
topically
applied thereto. As used herein, -decreasing TNFa production" and related
expressions refer
to reducing the amount of TNFa produced in response to an irritant, for
example, by
inhibiting the induction of TNFa in response to the irritant. Preferably, the
decrease in TNFa
production results in a perceptible reduction in redness, puffiness, and/or
swelling of the
affected area, although some TNFa production persists. For example, in some
embodiments,
TNFa production is reduced by at least about 10%, at least about 25%, at least
about 50%, at
least about 75%, or at least about 90%, compared to TNFa production in the
absence of a
composition comprising an anti-inflammatory agent. The extent of TNFa
production can be
determined by appropriate assays, e.g., in vitro assays described herein or
known in the art.
For example, Example 2 below provides experimental details of assays for
determining TNFa
production.
[0060] In some
embodiments, the cosmetic compositions for treating and/or
preventing inflammation, e.g., reducing redness or swelling, can further
comprise at least one
other anti-inflammatory agent, such as anti-acne agents. For example, the
cosmetic
composition comprising a modified yeast peptide fraction comprising metal-
complexed
peptide comprising SEQ ID NO:1 in an amount effective to treat and/or prevent
inflammation
may further comprise at least one other anti-inflammatory agent. Anti-
inflammatory agents
may include, for example, steroids, hydrocortisone, prcdnisone, prednisolone,
aspirin, aspirin
derivatives, aloe vera, willow bark, chamomile, and mixtures thereof; as well
as anti-irritants,
advanced glycation end-product (AGE) inhibitors, and immune system suppressing
agents.
In some embodiments, compositions of the invention include anti-acne agents,
such as, e.g.,
salicylic acid. Some such embodiments, further include glycolic acid. However,
in some
other embodiments, additional anti-acne agents, such as salicylic acid, are
excluded. Further,
it is contemplated that synergistic improvements may be obtained with
combinations of one
or more such additional anti-inflammatory agents with compositions of the
instant invention
in some embodiments.
Lipid Over-Production
[0061] In
certain preferred embodiments, the cosmetic compositions described herein
can be used to treat and/or prevent lipid over-production, for example, to
reduce excess
sebum output and/or cellulite. In some particularly preferred embodiments, a
composition
comprising an effective amount of a modified yeast peptide fraction comprising
a metal-
complexed peptide comprising SEQ ID NO:1 is topically applied to the skin, for
example to
24
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
an area of skin affected by lipid over-production. "Over-production of lipids"
or "lipid over-
production" refers to any production or secretion of oils and/or production or
deposition of
subcutaneous fat that is in excess of that desired by the individual. For
example lipid over-
production includes excess production, secretion, or accumulation of sebum, as
well as
excess production or accumulation of subcutaneous fat, such as cellulite.
[0062] Sebum is
an oily secretion containing fat, keratin, and cellular material,
produced by sebaceous glands, which are tiny ducts adjacent to hair follicles.
Sebum is
secreted onto the skin and hair (from the scalp). Excess sebum output is
associated with oily
skin and hair, and can contribute to conditions such as acne and oily dandruff
(seborrheic
dermatitis). Such problems are particularly common in adolescents, as the
increased levels
of sex hormones stimulate sebum over-production. Areas affected by lipid over-
production
include oily areas of the skin, e.g., oily facial skin or an area of the
scalp, as well as areas
affected by a skin condition associated with excess sebum output, such as acne
lesions.
[0063]
Cellulite is a lumpy uneven type of subcutaneous fat that accumulates
primarily on the buttocks and thighs of many women. A number of factors can
cause
cellulite including, hereditary, intestinal, circulatory, lymphatic, hormonal,
and lifestyle
factors. Cellulite is considered unsightly because it gives the tissues
underlying the skin an
"orange peel" or "cottage cheese" look, and pinching the skin can produce a
"mattress
appearance" with bulging and pitting of the fatty layer. Areas affected by
lipid over-
production include areas of cellulite, such as areas of the skin having the
"orange peel",
"cottage cheese" or "mattress" appearance. The term "treatment of cellulite"
includes the
amelioration of the visible signs of cellulite.
[0064] Treating
lipid over-production refers to eradicating, reducing, or ameliorating,
or reversing one or more of the unwanted features associated with over-
production of lipids.
Unwanted features associated with over-production of sebum, e.g., include
oily, shiny, acne-
prone skin, oily scalp, oily hair, dandruff-prone hair, or undesirable body
odors. Unwanted
features associated with over-production of subcutaneous fat, e.g., include
unsightly areas of
cellulite. Treatment benefits include, e.g., reducing the oily appearance of
affected skin or
hair, controlling surface oil, balancing sebum in oily-prone skin, visibly
minimizing pores,
reducing undesirable body odor due to accumulation of excess sebum, or
improving the
appearance of areas affected by cellulite deposition. Preventing lipid over-
production refers
to affording not yet affected skin a benefit that serves to avoid, delay,
forestall, or minimize
one or more unwanted features associated with lipid over-production, such as
reducing the
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
extent of oiliness, severity of acne, or lumpiness of cellulite, that
eventually develops at the
treated area. Modified yeast peptide fractions comprising metal-complexed
peptides
comprising SEQ ID NO:1 that are capable of treating and/or preventing lipid
over-production
can be referred to as "anti-lipid agents," which can act as, e.g., anti-oil
and/or anti-cellulite
agents. Compositions used to control lipid over-production will comprise an
effective
amount of modified yeast peptide fraction and/or metal-complexcd peptide(s)
comprising
SEQ ID NO:1 to treat and/or prevent lipid over-production, e.g., to reduce
acne and/or
cellulite.
[0065] Lipid
metabolism is partly controlled by the peroxisome proliferator-activated
receptors (PPARs), which form a superfamily of nuclear transcription factors.
The PPARs
are ligand-dependent intracellular proteins that stimulate transcription of
specific genes by
binding to specific DNA sequences in the nucleus following activation by the
appropriate
ligand. PPAR-y activity, in particular, is governed by binding of small
lipophilic ligands,
mainly fatty acids, derived from nutrition or metabolic pathways that
themselves are often
controlled by PPAR-y. Indeed, it is believed that PPAR-y a is the centerpiece
of a feed-
forward pathway that favors differentiation of and energy storage by
adipocytes. Without
wishing to be bound by theory, it is believed that the modified yeast peptide
fractions
comprising metal-complexed peptides comprising SEQ ID NO:1 can act to decrease
PPARs
signaling, particularly that of PPAR-y, thereby reducing lipid production and
acting as anti-
oil and/or anti-cellulite agents. For example, the compositions may act to
decrease induction
of PPAR-y, so that less is available for signaling adipocyte differentiation
and fat storage.
See Example 3 below.
[0066] Further,
it can be noted that the lipids whose production is reduced by certain
compositions of the instant invention are distinguished from membrane lipids,
such as those
found in lipid bilayers. Bilayer lipids include, for example, lipids in the
bilayers of the
stratum corneum, or other cutaneous lipids, such as cholesterol, cholesterol
esters, free fatty
acids, and ceramindes that make up the lipid bilayers of skin. See, e.g., U.S.
Pat. Appl. Pub.
No. 2006/0110815.
[0067] In
certain embodiments, the compositions of the instant invention comprise a
modified yeast peptide fraction and/or metal-complexed peptide comprising SEQ
ID NO:1 in
an amount sufficient to decrease PPARs signaling in a given area of skin when
topically
applied thereto. As used herein, -decreasing PPARs signaling" and related
expressions refer
to reducing the extent to which one or more PPARs (in particular PPAR-y) can
signal a cell
26
=
to produce and/or store lipids, e.g., by decreasing the expression of PPAR-y.
Preferably, the
decrease in PPARs signaling results in a perceptible reduction in oil or
cellulite at an affected
area, although some PPARs signaling and lipid production persists.
The extent of PPARs expression and/or signaling can be determined by
appropriate assays,
e.g., in vitro assays described herein or known in the art. For example,
Example 3 below
provides experimental details of assays for determining PPAR-y expression.
[0068] In some
embodiments, the cosmetic compositions for treating and/or
preventing lipid over-production, e.g., reducing sebum output or cellulite,
can further
comprise at least one other anti-lipid agent. For example, the cosmetic
composition
comprising a modified yeast peptide fraction comprising a metal-complexed
peptide
comprising SEQ ID NO:1 in an amount effective to treat and/or prevent lipid
over-production
may further comprise at least one other anti-lipid agent. Examples include,
without
limitation, certain anti-acne agents and other PPAR inhibitors, e.g., extracts
from Alisma
orientate. See, e.g., U.S. Patent No. 7,410,658. Further, it is contemplated
that synergistic
improvements may be obtained with combinations of one or more such additional
anti-lipid
agents with compositions of the instant invention, in some embodiments.
Signs of Aging
[0069] In certain
preferred embodiments, the cosmetic compositions described herein
can be used to treat and/or prevent signs of skin aging or other skin damage.
Signs of skin
aging include any dermatological signs of aging, including signs caused by
intrinsic
(chronological) aging, or caused by extrinsic factors (such as in photoaging).
The
compositions may be applied to skin already showing visible signs of aging, or
likely to show
such signs, e.g., due to age or sun exposure.
[0070] An early
sign of skin aging involves the gradual development of facial
wrinkles, whether fine surface lines or deeper creases and folds. While
wrinkling and other
signs of aging are intrinsic to skin, the process may be accelerated by
external factors, such as
excessive exposure to the sun and other damaging elements, overactive facial
expression
muscles, frequent use of tobacco products, poor nutrition, or certain skin
disorders. Fine
surface lines that progress to deeper creases, deepening facial wrinkles due
to repeated skin
folding, and deep folds that develop with maturity are visible changes
associated with aging.
27
CA 2768653 2017-08-30
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0071] Treating
signs of skin aging refers to eradicating, reducing, ameliorating, or
reversing one or more of the unwanted features associated with skin aging,
e.g., by reducing
loss of skin firmness or plumpness to a perceptible extent. For example,
compositions and
methods of the instant invention may be used to reverse or treat signs of skin
aging once
manifested, such as is common in individuals over 25 years of age. Preventing
signs of skin
aging refers to affording skin a benefit that serves to avoid, delay,
forestall, or minimize one
or more unwanted features associated with aging, e.g., by slowing the loss of
firmness or
plumpness as the skin eventually ages. That is, the compositions and methods
of the instant
invention may be employed prophylactically, e.g., to forestall signs of skin
aging in
individuals that have not yet manifested signs of skin aging, most commonly in
individuals
under 25 years of age.
[0072] Modified
yeast peptide fractions comprising metal-complexed peptides
comprising SEQ ID NO:1 that are capable of treating and/or preventing signs of
aging can be
referred to as "anti-aging agents." Compositions used to as anti-aging agents
will comprise
an effective amount of a modified yeast peptide fraction and/or metal-
complexed peptide
comprising SEQ ID NO:1 to treat and/or prevent signs of aging. Some
particularly preferred
embodiments provide compositions for topical application which comprise an
effective
amount of a zinc-complexed peptide comprising SEQ ID NO:1 to treat and/or
prevent signs
of aging. Treatment and/or prevention generally results in an improvement in
one or more
unwanted features and/or in the overall aesthetic appearance of the treated
skin.
[0073] The
improvement in the unwanted feature and/or overall aesthetic appearance
can include one or more of the following: reducing dermatological signs of
chronological
aging, photo-aging, hormonal aging, and/or actinic aging; preventing and/or
reducing the
appearance of lines and/or wrinkles; reducing the noticeability of facial
lines and wrinkles,
facial wrinkles on the cheeks, forehead, perpendicular wrinkles between the
eyes, horizontal
wrinkles above the eyes, and around the mouth, marionette lines, and
particularly deep
wrinkles or creases; preventing, reducing, and/or diminishing the appearance
and/or depth of
lines and/or wrinkles; improving the appearance of suborbital lines and/or
periorbital lines;
reducing the appearance of crow's feet; rejuvenating and/or revitalizing skin,
particularly
aging skin; reducing skin fragility; preventing skin atrophy; improving skin
tone, radiance,
and/or clarity; preventing, reducing, and/or ameliorating skin sagging;
improving skin
firmness, plumpness, tautness, suppleness and/or softness; improving skin
texture and/or
promoting retexturization; improving skin barrier repair and/or function;
improving the
28
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
appearance of skin contours; restoring skin luster and/or brightness;
minimizing
dermatological signs of fatigue and/or stress; resisting environmental stress;
replenishing
ingredients in the skin decreased by aging and/or menopause, such as essential
nutrients or
other skin constituents; ameliorating the effects of estrogen imbalance;
improving
communication among skin cells; increasing cell proliferation and/or
multiplication;
increasing skin cell metabolism decreased by aging and/or menopause; retarding
cellular
aging; improving skin moisturization and/or hydration; enhancing skin
thickness; increasing
skin elasticity and/or resiliency; improving procollagen and/or collagen
synthesis; enhancing
exfoliation; improving microcirculation; reducing dryness; and any
combinations thereof.
[0074] In certain preferred embodiments, the compositions and methods of
the
invention are directed to the treatment and/or prevention of fine lines or
wrinkles in the skin.
In the case of treatment, the compositions are applied to skin in need of such
treatment, by
which is meant skin having wrinkles and/or fine lines. The fine lines and/or
wrinkles may
occur on any surface of the skin, including without limitation, the skin of
the hands, arms,
.. legs, neck, chest, and face, including the forehead. Preferably, the
compositions are applied
directly to the fine lines and/or wrinkles. For example, methods for treating
fine lines and
wrinkles may comprise topically applying a composition described herein to
skin in need
thereof, e.g., topically applying directly to a fine line and/or wrinkle in an
amount and for a
time sufficient to reduce the severity of the fine lines and/or wrinkles. The
effect of a
.. composition on the appearance of fine lines and wrinkles can be evaluated
qualitatively, e.g.,
by visual inspection, or quantitatively, e.g., by microscopic or computer
assisted
measurements of wrinkle morphology (e.g., the number, depth, length, area,
volume and/or
width of wrinkles per unit area of skin).
[0075] The term
"wrinkle" or "wrinkling" refers to both fine wrinkling and/or coarse
.. wrinkling. Fine wrinkling or fine lines refers to superficial lines and
wrinkles on the skin
surface. Coarse wrinkling refers to deep furrows, particularly deep
lines/wrinkles on the face
and around the eyes, including expression lines such as frown lines and
wrinkles, forehead
lines and wrinkles, crow's feet lines and wrinkles, nasolabial folds, and
marionette lines and
wrinkles. Forehead lines and wrinkles refer to superficial lines and/or deep
furrows on skin
of the forehead. Crow's feet lines and wrinkles refer to superficial lines
and/or deep furrows
on skin around the eye area. Marionette lines and wrinkles refer to
superficial lines and/or
deep furrows on skin around the mouth.
29
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0076] In
certain preferred embodiments, the compositions and methods of the instant
invention are directed to improving skin firmness, plumpness, and/or tautness.
In certain
preferred embodiments, the compositions and methods of the instant invention
are directed to
increasing and/or preventing loss of skin elasticity. Elasticity of skin
refers to the skin's
springiness and/or resilience, due to the skin's ability to regain its
original shape and size
after deformation. Elasticity of the skin may be evaluated by a pinch test
that can cause
deformation by either stretching or squeezing the skin.
[0077] Loss of
firmness, wrinkling and other signs of aging result in part from loss of
skin collagen over time. As used herein "collagen" is used interchangeably
with "collagen I"
or "collagen type I," the type present in skin as a dermal matrix component.
Collagen I is
composed of three protein chains wound together in a tight triple helix, which
provides a
tensile strength greater than that of steel. It is created by fibroblasts,
specialized skin cells
located in the dermis. Formation involves the production of preprocollagen I
by ribosomes
along the rough endoplasmic reticulum (RER); conversion to procollagen I and
formation of
the triple helical structure within the RER; and eventual formation of
tropocollagen outside
the cell, the form that aggregates to give collagen fibrils and then fibers.
Collagen gives skin
firmness, strength, durability, and a youthful smooth, plump appearance.
Without wishing to
be bound by theory, it is believed that the modified yeast peptide fractions
comprising metal-
complexcd peptides comprising SEQ ID NO:1 can act to increase collagen
production and
thus collagen skin levels, thereby delaying one or more of the unwanted
features associated
with skin aging, e.g., by instead maintaining skin firmness and plumpness. See
Example 4
below.
[0078] In
certain embodiments, the compositions of the instant invention comprise a
modified yeast peptide fraction and/or metal-complexed peptide comprising SEQ
ID NO:1 in
an amount sufficient to increase collagen synthesis in given area of skin when
topically
applied thereto. As used herein, "increasing collagen synthesis" and related
expressions refer
to stimulating, inducing, or up-regualting procollagen and/or collagen
production to increase
the collagen content in an area of skin, preferably improving skin firmness
and/or plumpness
to a perceptible extent. For example, in some embodiments, collagen synthesis
is increased
by at least about 10%, at least about 25%, at least about 50%, at least about
75%, or at least
about 90%, compared to the synthesis of collagen in the absence of the
composition. The
extent of collagen and/or collagen synthesis in the skin can be determined by
appropriate
assays, e.g., in vitro assays described herein or known in the art. The levels
of one or more
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
collagen precursors can also be determined as indicative of the level of skin
collagen, and
such in vitro assays are also known in the art. For example, Example 4 below
provides
experimental details of assays for measuring procollagen I levels in human
dermal
fibroblasts.
[0079] While collagen is created by fibroblasts, its degradation is
normally controlled
by the matrix metalloprotcinases (MMPs). Gross J, et al. Biochein Biophys Res
Commun
1974;61:605-12. MMPs are a family of related zinc-dependent proteases having
over 25
members and including the metalloproteinases (MMP-1, -8, and -13) and the
gelatinases
(MMP-2 and 9). Degradation of collagen by MMPs is associated with loss of
firmness and
elasticity of the skin. For example, collagen degradation leads to abnormal
cross-linking of
the collagen fibers to produce rigid, less flexible structures. Without
wishing to be bound by
theory, it is believed that the modified yeast peptide fractions comprising a
metal-complexed
peptide comprising SEQ ID NO:1 can act as metalloproteinase inhibitors,
decreasing
metalloproteinase activity and thereby reducing loss of collagen and
associated unwanted
features of skin aging. See Example 5 below.
[0080] In
certain embodiments, the compositions of the instant invention comprise a
modified yeast peptide fractions comprising a metal-complexed peptide
comprising SEQ ID
NO:1 in an amount sufficient to decrease metalloproteinase activity in given
area of skin
when topically applied thereto. As used herein, "decreasing metalloproteinase
activity" and
related expressions refer to inhibiting, down-regulating, or reducing the
activity of one or
more enzymes of the metalloproteinase superfamily.
Preferably, the decrease in
metalloproteinase activity reduces collagen loss in the skin to a perceptible
extent, although
some metalloproteinase activity persists. For
example, in some embodiments,
metalloproteinase activity is reduced by at least about 10%, at least about
25%, at least about
50%, at least about 75%, or at least about 90%, compared to the activity of
the
metalloproteinase in the absence of a composition comprising a
metalloproteinase inhibitor.
The extent of metalloproteinase activity and/or inhibition can be determined
by appropriate
assays, e.g., in vitro assays described herein or known in the art. For
example, Example 5
below provides experimental details of assays for measuring metalloproteinase
activity and
inhibition.
[0081] Loss of
hyaluronic acid over time also plays a role in skin aging. Hyaluronic
acid is a glycosaminoglycan (GAG) found in the skin as part of the ECM. GAGs
are long
unbranched polymers of repeating disaccharide units, mainly composed of
hexosamine,
31
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
hexose, hexuronic acid moieties, or sulfates thereof. GAGs bind to proteins in
the skin to
form proteoglycans, which contribute to the growth, preservation, and repair
of skin.
Hyaluronic acid, in particular, has been reported to be responsible for
hydration of the skin,
nutrient exchange, and protection against free radicals. Wiest et al. J Dtsch
Dermatol Ges.
.. 2008 Mar;6(3):176-80; Bert et al. Biorheology. 1998 May-Jun;35(3):211-9. It
also has been
reported, however, that as skin ages over time, GAG synthesis declines and the
overall GAG
content in the skin decreases. Smith et al. in J. Invest. Dermatol., 1962, 39,
pages 347-350;
Fleischmajer et al. Biochim. Biophys. Acta, 1972, 279, pages 265-275; Longas
et al.
Carbohydr. Res., 1987, 159, pages 127-136. This reduction in GAG and
hyaluronic acid
content in the skin is believed to contribute to age-related changes in the
mechanical
properties of skin, particularly changes in tissue hydration and resiliency.
Caffino et al., Arch
Biochem Biophys. 2000 Jan 1;373(1):91-101; Vogel et al., Z Gerontol. 1994 May-
Jun;27(3):182-5; Lanir et al., J Biomech Eng. 1990 Feb;112(1):63-9). Without
wishing to be
bound by theory, it is believed that the modified yeast peptide fractions
comprising a metal-
.. complexed peptide comprising SEQ ID NO:1 can act to increase hyaluronic
acid production,
thereby reducing one or more of the unwanted features associated with skin
aging, e.g., by
improving skin hydration and resiliency. See Example 6 below.
[0082] In
certain preferred embodiments, the compositions and methods of the instant
invention are directed to improving skin moisturization and/or hydration. For
example, in
certain embodiments, the compositions of the instant invention comprise a
modified yeast
peptide fraction comprising a metal-complexed peptide comprising SEQ ID NO:1
in an
amount sufficient to increase hyaluronic acid production in a given area of
skin when
topically applied thereto. As used herein, "increasing hyaluronic acid
production" and related
expressions refer to stimulating, inducing, or up-regulating hyaluronic acid
synthesis to
increase the hyaluronic acid content in an area of skin, preferably improving
skin hydration
and/or resiliency by a perceptible amount. For example, in some embodiments,
hyaluronic
acid production is increased by at least about 10%, at least about 25%, at
least about 50%, at
least about 75%, or at least about 90%, compared to the production of
hyaluronic acid in the
absence of the composition. The extent of hyaluronic acid and/or hyaluronic
acid production
.. in the skin can be determined by appropriate assays, e.g., in vitro assays
described herein or
known in the art. For example, Example 6 below provides experimental details
of assays for
measuring hyaluronic acid levels in human dermal fibroblasts.
32
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0083]
Exfoliating enzymes in the skin, such as the KLKs, are also involved in skin
aging. KLKs are a family of proteases residing in the stratum comeum of human
skin that
aid exfoliation of dead skin cells by breaking down proteins responsible for
cell-to-cell
cohesion. Kishibe M et al. 2006 "Kallikrein 8 Is Involved in Skin Desquamation
in
Cooperation with Other Kallikreins." J. Biol. Chem. 282: 5834-5841. In the
stratum
comeum, cell-to-cell cohesion depends primarily on proteins known as the
comeodesmosomes. Comeodesmosomes are known to be broken down by KLKs during
skin
remodeling and renewal, allowing dead cells to slough off of the skin surface.
This
exfoliation of dead cells improves the skin's aesthetic appearance, e.g., by
preventing build
up of dead cells on the skin surface that give the skin a dry, rough, dull
appearance.
Exfoliation can leave skin feeling smoother and looking fresher, and may also
augment
penetration of other skin actives. It is believed that with age, however,
comeodesmosome
turnover slows down, allowing a build up of dead cells on the skin surface.
Without wishing
to be bound by theory, it is believed that the modified yeast peptide
fractions comprising
metal-complexed peptide comprising SEQ ID NO:1 can act to increase KLKs
activity,
thereby reducing one or more unwanted features associated with skin aging,
e.g., reducing
dryness and/or improving skin luster and/or brightness. See Example 7 below.
Up-
regulation of KLK activity can increase the rate of shedding dead skin, and
thus naturally
enhance skin exfoliation.
[0084] Accordingly, in certain preferred embodiments, the compositions
described
herein can be used to enhance exfoliation. In some particularly preferred
embodiments, a
composition comprising an effective amount of a modified yeast peptide
fraction and/or
metal-complexed peptide comprising SEQ ID NO:1 is topically applied to the
skin, e.g., to an
area of skin in need of exfoliation. An area of skin in need of exfoliation
includes any skin
surface that would benefit from an increase in the rate of removal of dead
cells building up on
the skin surface, for example, as may be common in individuals over 25 years
of age, and in
particular areas of dry skin. Exfoliation of dry skin can produce a fresher,
smoother look of
the area. Areas of skin in need of exfoliation also include areas where it is
desirable to
increase or augment penetration of a skin active being topically delivered.
Areas of skin in
.. need of exfoliation also include areas prone to acne, e.g., where
exfoliation can help stop
acne before it starts, e.g., by removing pore-clogging dirt and oil to reveal
fresher, brighter
skin and/or a shine-free finish. Areas that can benefit from enhanced
exfoliation include,
without limitation, the skin of the hands, arms, legs, neck, chest, and face,
including the
33
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
forehead. In particular, the skin of the joints and feet tend to accumulate
dead skin cells,
leading to rough, dry, dull, wrinkled, and/or discolored skin in such areas.
[0085] In some
even more preferred embodiments, a composition described herein is
topically applied to the skin of the elbows, knees, ankles, feet, soles of the
feet, heels, and the
like, areas that may particularly benefit from enhanced exfoliation. In some
preferred
embodiments, a composition described herein is topically applied an area of
dry skin, areas
that typically also benefit from enhanced exfoliation. Modified yeast peptide
fractions
comprising metal-complexed peptides comprising SEQ ID NO:1 that are capable of
enhancing exfoliation can be referred to as "exfoliating agents." Compositions
used to as
exfoliating agents will comprise an effective amount of modified yeast peptide
fraction
and/or metal-complexed peptide(s) comprising SEQ ID NO:1 to improve or enhance
exfoliation in a given area of skin when topically applied thereto.
[0086] More
particularly, in certain embodiments, compositions of the instant
invention comprise a modified yeast peptide fraction comprising metal-
complexed peptide
comprising SEQ ID NO:1 in an amount sufficient to increase KLKs activity in a
given area of
skin when topically applied thereto. As used herein "increasing KLKs activity"
and related
expressions refer to stimulating, inducing, or up-regulating the proteolytic
activity of one or
more protease enzymes of the KLKs family, to increase removal of dead skin
cells from an
area of skin. Preferably, the increase in KLKs activity increases the rate of
exfoliation of
.. dead cells from the skin surface to a perceptible extent, such that, for
example, an
improvement is observed in skin luster and/or brightness; and/or an
improvement is observed
in skin tone, radiance, and/or clarity. For example, in some embodiments, KLKs
activity is
increased by at least about 10%, at least about 25%, at least about 50%, at
least about 75%, or
at least about 90%, compared to the activity of the KLK protease in the
absence of the
composition. The extent of exfoliation and/or KLKs activity in the skin can be
determined by
appropriate assays, e.g., in vitro assays described herein or known in the
art. For example,
Example 7 below provides experimental details of assays for measuring the
activity of
recombinant human KLK5.
[0087] In some
embodiments, methods for enhancing exfoliation further comprise
rubbing the composition comprising an exfoliating agent against the skin
surface. Such
rubbing generally involves pressing the composition against the skin, and
moving it around
on the skin, preferably repeatedly, and more preferably repeatedly in circular
motions. By
"repeatedly" is meant about two, about three, about five, about ten times or
more, e.g., to help
34
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
slough away dead skin cells loosened by the proteolytic-enhancing properties
of the
composition. Rubbing may be gentle or vigorous, depending, e.g., on the area
being
exfoliated. Following exfoliation, the area of skin generally is rinsed, for
example, with cool
water, and then moisturized to protect the exfoliated skin surface.
[0088] In certain embodiments, the compositions of the instant invention
comprise a
modified yeast peptide fraction comprising a metal-complexed peptide
comprising SEQ ID
NO:1 in an amount sufficient to bring about two or more of the following:
increase in KLKs
activity, increase in hyaluronic acid production, increase in collagen
synthesis, and decrease
in metalloproteinase activity, in a given area of skin when topically applied
thereto. Without
wishing to be bound to theory, two or more such combined actions, targeted
against different
aging processes, may have synergistic results in treating and/or preventing
signs of skin
aging.
[0089] Further,
the skin-lightening, anti-inflammatory, and/or anti-lipid properties of
the compositions described herein can also contribute to their anti-aging
properties. For
example, inflammation has been shown to activate various matrix degrading
metalloproteases, leading to abnormal matrix degradation that may contribute
to skin aging.
Pillai, et al. (2005) Int J Cosmet Sci. Feb;27(1):17-34. Inflammation also has
been shown to
exacerbate intrinsic and extrinsic aging of human skin by causing an
accumulation of reactive
oxygen species, which damage cellular proteins, lipids and carbohydrates that
then
accumulate in dermal and epidermal compartments. Pillai, et al. (2005) Int J
Cosmet Sci.
Feb;27(1):17-34; Bissett, et al. (1990) Photodermatol. Photoimmunol. Photomed
7:153-8;
Thornfeldt, CR (2008) J. Cosmet. Dermatol. 7:78-82. Inflammation is known to
also
contribute to skin discoloration, for example, hyper-pigmentation in the skin
has been
observed post-inflammation. Ruiz-Maldonado et al. (1997) Semin Cutan Med Surg.
16(1):36-43; Tomita et al. (1989) Dermatologica. 179 Suppl 1:49-53); Holland
et al. Semin
Cutan Med Surg. 2005 Jun;24(2):79-83. Skin discoloration, along with oiliness
and/or areas
of cellulite, can further contribute to an appearance of aging. Again without
wishing to be
bound to theory, the combined actions of compositions described herein can
provide
synergistic skin benefits, in certain embodiments, e.g., by exhibiting two or
more of the
following modulatory activities: decreasing melanin synthesis, decreasing TNFa
production,
decreasing PPARs signaling, decreasing metalloproteinase activity, increasing
collagen
synthesis, increasing hyaluronic acid production, and increasing KLKs
activity.
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0090] In some
embodiments, the cosmetic compositions for treating and/or
preventing signs of skin aging can further comprise additional exfoliating
and/or anti-aging
agents. For example, the cosmetic composition comprising a modified yeast
peptide fraction
comprising metal-complexed peptide comprising SEQ ID NO:1 in an amount
effective to
treat and/or prevent signs of skin aging may further comprise at least one
other exfoliating
and/or anti-aging agent. It is contemplated that synergistic improvements may
be obtained
with such combinations, in some embodiments.
[0091]
Exemplary exfoliating agents include, without limitation, alpha-hydroxyacids,
beta-hydroxyacids, oxaacids, oxadiacids, and their derivatives such as esters,
anhydrides, and
salts thereof. Suitable hydroxy acids include, for example, glycolic acid,
lactic acid, malic
acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, mandelic acid,
salicylic acid, and
derivatives thereof, as well as fruit enzymes, such as pineapple enzyme. A
preferred
additional exfoliating agent is glycolic acid
[0092]
Exemplary anti-aging agents include, without limitation, botanicals (e.g.,
Butea Frondosa extract); thiodipropionic acid (TDPA) and esters thereof;
retinoids (e.g., all-
trans retinoic acid, 9-cis retinoic acid, phytanic acid and others); hydroxy
acids (including
alpha-hydroxyacids and beta-hydroxyacids), salicylic acid and salicylates;
antioxidants,
exfoliating agents (e.g., glycolic acid, 3,6,9-trioxaundecanedioic acid,
etc.), estrogen
synthetasc stimulating compounds (e.g., caffeine and derivatives); compounds
capable of
inhibiting 5 alpha-reductase activity (e.g., linolenic acid, linoleic acid,
finasteride, and
mixtures thereof); barrier function enhancing agents (e.g., ceramides,
glycerides, cholesterol
and its esters, alpha-hydroxy and omega-hydroxy fatty acids and esters
thereof, etc.);
collagenase inhibitors; and clastase inhibitors; anti-aging botanicals,
keratolytic agents,
desquamating agents, keratinocyte proliferation enhancers, and skin plumpers
that serve as
additional collagen enhancers to the skin, to name a few. An example of a
suitable skin
plumper is palmitoyl oligopeptide. Other skin plumpers include other collagen
and/or other
glycosaminoglycan (GAG) enhancing agents. Exemplary retinoids include, without
limitation, retinoic acid (e.g., all-trans or 13-cis) and derivatives thereof,
retinol (Vitamin A)
and esters thereof, such as retinol palmitate, retinol acetate and retinol
propionate, and salts
thereof. In some embodiments, the invention relates to synergistic action of
one or more
compositions described herein with TDPA, e.g., to provide enhanced anti-aging
benefits to
skin. Additional examples of anti-aging agents are provided below.
36
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0093] Based on
the teachings provided herein, one of skill in the art will recognize
other cosmetic and/or pharmaceutical applications for the compositions
described herein, and
such applications are also contemplated as within the scope of the instant
invention. For
example, compositions described herein may also find use in personal care
products, such as
skin care products or hair care products, where it is desirable to produce a
skin benefit
described herein upon application of the product. Personal care products for
the skin include,
for example, underarm deodorants. It is contemplated, for example, that
compositions
described herein can find use in underarm formulations that lighten the skin
under the arms,
e.g., where the under-arm area has become or is becoming darker than desired.
[0094] The invention provides methods for providing a skin benefit by
topically
applying a composition comprising a modified yeast peptide fraction comprising
metal-
complexed peptide comprising SEQ ID NO:1, and/or other calcium influx
inhibitor, over an
area of skin for a period of time sufficient to produce one or more of the
benefits described
herein. The composition will typically be applied to the skin one, two, or
three times daily
for as long as is necessary to achieve desired results, such as the
exfoliating, anti-aging, anti-
lipid, anti-inflammatory and/or skin (or hair) lightening benefits, as
described herein. This
treatment regiment may comprise daily application or every-other-day
application for at least
about one week, at least about two weeks, at least about four weeks, at least
about eight
weeks, at least about twelve weeks, or more. For example, in some embodiments
directed
against acne, inventive compositions may be applied morning and/or evening,
e.g., by gently
smoothing the product over the face, preferably to cleansed dry skin. Chronic
treatment
regimens are also contemplated, e.g., with respect to prophylactic treatments
aimed at
forestalling one or more signs of skin aging or other unwanted skin features,
such as acne.
[0095] The
cosmetic compositions described herein find use in exfoliating, anti-
aging, anti-lipid, anti-cellulite, anti-inflammatory, and/or skin (or hair)
lighting products,
preferably formulated for topical application to the skin (or hair), e.g.,
with a cosmetically
acceptable vehicle, as detailed below.
Cosmetic Formulations of Modified Peptide Fractions & Related Compositions
[0096] The
compositions described herein can be formulated as a variety of skin or
.. hair care products for topical application. The composition may be
formulated in a variety of
product forms suitable for application to the skin (including the scalp)
and/or hair, such as,
for example, a lotion, cream, serum, spray, aerosol, cake, ointment, essence,
gel, paste, patch,
pad, pencil, pomade, solution, towelette, mask, stick, foam, elixir, mousse,
powder, bath salt,
37
foaming cleanser, concentrate, or any other liquid, semi-solid, or solid form.
Preferably the
composition is formulated as a lotion, cream, essence, ointment, or gel, and
in particular a
lotion, toner pad or cleanser, e.g., for anti-acne products. Exemplary
formulations for an
.. essence are provided in Examples 8, 9, and 13, below. Exemplary
formulations for a cream
formula and a daytime cram formula are provided below in Examples 10 and 11,
respectively. Exemplary formulation for a foaming cleanser formulation is
provided in
Example 12 below.
[0097] The compositions will comprise an effective amount of a modified
yeast
peptide fraction, and/or metal-coinplexed peptide comprising SEQ ID NO:1,
and/or calcium
influx inhibitor, by which is meant an amount sufficient to impart to the
formulated product
one or more desired properties or modulatory activities, such as acting as a
skin (or hair)
lightener, anti-inflammatory agent, anti-lipid agent, exfoliating agent,
and/or an anti-aging
agent. For example, the modified peptide fraction or metal-cornplexed peptide
comprising
SEQ ID NO:] may be present in an amount from about 0.001 weight % to about 5
weight %
based on the total weight of the composition; preferably from about 0.01
weight % to about 3
weight % based on the total weight of the composition; and more preferably
from about 0.1
weight % to about 2 weight %, or about 1 weight %, based on the total weight
of the
composition.
[0098] The compositions can include a cosmetically acceptable vehicle. A
cosmetically acceptable vehicle refers to any vehicle, for a cosmetic, drug or
medicament that
is suitable for use in direct, safe contact with human tissues and/or human
hair, and may
include, e.g., any diluent, solvent, carrier, filler, or the like. Such
vehicles may take the form
of any known in the art suitable for application to skin (or hair) and may
include water (e.g.,
deionized water); vegetable oils; mineral oils; esters such as octal
palmitate, isopropyl
rnyristate, and isopropyl palmitate; ethers such as dicapryl ether and
dimethyl isosorbide;
alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl
alcohol, cetearyl
alcohol, stearyl alcohol, and biphenyl alcohol; isoparaffins such as
isooctane, isododecane,
and isohexadecane; silicone oils such as cyclomethicone, dimethicone,
dimethicone cross-
polymer, polysiloxanes, and their derivatives, preferably organo-rnodified
derivatives;
hydrocarbon oils such as mineral oil, petrolatum, isoeicosane, and
polyisobutene; polyols
such as propylene glycol, glycerin. butylene glycol, pentylene glycol, and
hexylene glycol;
waxes such as beeswax and botanical waxes; or any combinations or mixtures of
the
38
CA 2768653 2017-08-30
CA 02768653 2016-10-31
foregoing. Based on the teachings herein, a person skilled in the art will be
able to select a
suitable vehicle, and/or in an amount thereof, such that one or more of the
desired properties
of the cosmetic compositions of the instant invention can be preserved.
[0099] The vehicle may comprise an aqueous phase, an oil phase, an
alcohol phase, a
silicone phase, or mixtures thereof. The cosmetically acceptable vehicle may
also comprise
an emulsion. Non-limiting examples of suitable emulsions include water-in-oil
emulsions,
oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone
emulsions, wax-in-
water emulsions, water-oil-water triple emulsions, or the like having the
appearance of a
cream, gel, or microemulsions. The emulsion may include an emulsifier, such as
a nonionic,
anionic or amphoteric surfactant.
[0100] The oil phase of the emulsion preferably has one or more organic
compounds,
including emollients; humectants, such as butylene glycol, propylene glycol,
Methyl gluceth-
20, and glycerin; other water-dispersible or water-soluble components,
including thickeners
TM
such as veegum or hydroxyalkyl cellulose; gelling agents, such as high MW
polyaerylie acid,
TM
such as CARBOPOL 934; and mixtures thereof. The emulsion may have one or more
emulsifiers capable of emulsifying the various components present in the
composition.
[0101] The compounds suitable for use in the oil phase include without
limitation,
vegetable oils; esters such as octyl palmitate, isopropyl myristate, and
isopropyl palmitate;
ethers such as dicapryl ether; fatty alcohols such as cetyl alcohol, stearyl
alcohol, and behenyl
alcohol; isoparaffins such as isooctane, isododecane, and isohexadecane;
silicone oils such as
dimethicones, cyclic silicones, and polysiloxanes; hydrocarbon oils such as
mineral oil,
petrolatum, isoeicosane, and polyisobutene; natural or synthetic waxes; and
the like. The oil-
containing phase may be composed of a single oil or mixtures of different
oils. Suitable
hydrophobic hydrocarbon oils may be saturated or unsaturated, have an
aliphatic character,
be straight or branched chained, or contain alicyclic or aromatic rings.
Hydrocarbon oils
include those having 6-20 carbon atoms, more preferably 10-16 carbon atoms.
Representative hydrocarbons include decane, dodecane, tetradecane, tridecane,
and C8-2.0
isoparaffins. Paraffinic hydrocarbons are available from Exxon under the
ISOPARS
trademark, and from the Permethyl Corporation. In addition, Cs_20 paraffinic
hydrocarbons
such as C12 isoparaffin (isododecane) manufactured by the Permethyl
Corporation having the
tradename Pennethyl 99ATM are also contemplated to be suitable. Various
commercially
available C16 isoparaffins, such as isohexadecane (having the tradename
Permethylain are
also suitable. Examples of preferred volatile hydrocarbons include
polydecanes, such as
39
CA 02768653 2016-10-31
isododecane and isodecane, including for example, Permethy1-99A (Presperse
Inc.) and the
C7-C8 through C12-C15 isoparaffins such as the Isopar Series, available from
Exxon
Chemicals. A representative hydrocarbon solvent is isododecane.
[0102] The oil phase may
comprise one or more waxes, including for example, rice
bran wax, camauba wax, ouricurry wax, candelilla wax, montan waxes, sugar cane
waxes,
ozokerite, polyethylene waxes, Fischer-Tropsch waxes, beeswax, microcrystaline
wax,
silicone waxes, fluorinated waxes, and any combination thereof.
10103] Non-limiting
emulsifiers include emulsifying waxes, emulsifying polyhydric
alcohols, polyether polyols, polyethers, mono- or di-ester of polyols,
ethylene glycol mono-
stearates, glycerin mono-stearates, glycerin di-stearates, silicone-containing
emulsifiers, soya
sterols, fatty alcohols such as cetyl alcohol, acrylates, fatty acids such as
stearic acid, fatty
acid salts, and mixtures thereof. Some preferred emulsifiers include soya
sterol, cetyl
alcohol, stearic acid, emulsifying wax, acrylates, silicone containing
emulsifiers, and
mixtures thereof. Other specific emulsifiers that can be used with the
compositions described
herein include, but are not limited to, one or more of the following: C10-30
alkyl acrylate
crosspolymer; Dimethicone PEG-7 isostearate; acrylamide copolymer; mineral
oil; sorbitan
esters; polyglyeery1-3-diisostearate; sorbitan monostearate; sorbitan
tristearate; sorbitan
sesquioleate; sorbitan monooleate; glycerol esters such as glycerol
monostearate and glycerol
monooleate; polyoxyethylene phenols such as polyoxyethylene octyl phenol and
polyoxyethylene nonyl phenol; polyoxyethylene ethers such as polyoxyethylene
cetyl ether
and polyoxyethylene steatyl ether; polyoxyethylene glycol esters;
polyoxyethylene sorbitan
esters; dimethicone copolyols; polyglyceryl esters such as polyglycery1-3-
diisosteamte;
glyceryl laurate; Steareth-2, Steareth-10, and Steareth-20, to name a few.
Additional
emulsifiers are provided in the INCI Ingredient Dictionary and Handbook 11th
Edition 2006,
These emulsifiers typically will
be present in the composition in an amount from about 0.001% to about 10% by
weight, in
particular in an amount from about 0.01% to about 5% by weight, and more
preferably, from
about 0.1% to about 3% by weight. Based on the teachings herein, a person
skilled in the art
will be able to select a suitable emulsifier, or any other materials described
herein, and/or in
an amount thereof, such that one or more of the desired properties of the
cosmetic
compositions of the instant invention can be preserved.
[0104] The oil phase may
comprise one or more volatile and/or non-volatile silicone
oils. Volatile silicones include cyclic and linear volatile dimethylsiloxane
silicones. In some
CA 02768653 2016-10-31
embodiments, the volatile silicones may include cyclodimethicones, including
tetramer (D4),
pentamer (D5), and hexamer (D6) cyclomethicones, or mixtures thereof.
Particular mention
may be made of the volatile cyclomethicone-hexamethyl cyclotrisiloxane,
octamethyl-
cyclotetrasiloxane, and decamethyl-cyclopentasiloxane. Suitable dimethicones
are available
from Dow Corning under the name Dow Corning 200 Fluid and have viscosities
ranging
from about 0.65 to about 600,000 centistokes or higher. Suitable non-polar,
volatile liquid
silicone oils are disclosed in U.S. Pat. No. 4,781,917.
Additional volatile silicones materials are described in Todd et al.,
"Volatile
Silicone Fluids for Cosmetics", Cosmetics and Toiletries, 91:27-32 (1976),
Linear volatile silicones generally have a viscosity
of less than about 5 centistokes at 25 C, whereas the cyclic silicones have
viscosities of less
than about 10 centistokes at 25 C. Examples of volatile silicones of varying
viscosities
TM
include Dow Corning 200, Dow Coming 244, Dow Corning 245, Dow Corning 344, and
Dow Corning 345, (Dow Coming Corp.); SF-1204 and SF-1202 Silicone Fluids (G.E.
Silicones); GE 7207 and 7158 (General Electric Co.); and SWS-03314 (SWS
Silicones
Corp.). Linear, volatile silicones include low molecular weight
polydimethylsiloxane
compounds such as hexamethyldisiloxane, octamethyltrisiloxane,
decamethyltetrasiloxane,
and dodecamethylpentasiloxane, to name a few.
101051 Non-volatile
silicone oils will typically comprise polyalkylsiloxanes,
polyarylsiloxanes, polyalkylarylsiloxanes, or mixtures thereof.
Polydimethylsiloxanes are
preferred non-volatile silicone oils. The non-volatile silicone oils will
typically have a
viscosity from about 10 to about 60,000 centistokes at 25 C, preferably
between about 10 and
about 10,000 centistokes, and more preferred still between about 10 and about
500
centistokes; and a boiling point greater than 250 C at atmospheric pressure.
Non limiting
examples include dimethyl polysiloxane (dimethicone), phenyl trimethicone, and
diphenyldimethicone. The volatile and non-volatile silicone oils may
optionally be
substituted will various functional groups such as alkyl, aryl, amine groups,
vinyl, hydroxyl,
haloallcyl groups, allcylaryl groups, and acrylate groups, to name a few.
101061 The water-in-
silicone emulsion may be emulsified with a nonionic surfactant
(emulsifier) such as, for example, polydiorganosiloxane-polyoxyalkylene block
copolymers,
including those described in U.S. Patent No. 4,122,029.
These emulsifiers generally comprise a polydiorganosiloxane
backbone, typically polydimethylsiloxane, having side chains comprising
¨(EO)m¨ and/or ¨
41
CA 02768653 2016-10-31
(P0).¨ groups, where EO is ethylcneoxy and PO is 1,2-propyleneoxy, the side
chains being
typically capped or terminated with hydrogen or lower alkyl groups (e.g.,
C1.6, typically C1.3).
Other suitable water-in-silicone emulsifiers are disclosed in U.S. Patent No.
6,685,952.
Commercially available
water-in-silicone emulsifiers include those available from Dow Coming under
the trade
designations 3225C and 5225C FORMULATION AID; SILICONE SF-1528 available from
Th
General Electric; AB1L EM 90 and EM 97, available from Goldschmidt Chemical
TM
Corporation (Hopewell, VA); and the SILWET series of emulsifiers sold by OSI
Specialties
(Danbury, CT).
[0107] Examples of water-in-silicone emulsifiers include, but are not
limited to,
dimethicone PEG 10/15 crosspolymer, dimethicone copolyol, cetyl dimethicone
copolyol,
PEG-15 lauryl dimethicone crosspolymer, laurylmethicone crosspolymer,
cyclomethicone,
dimethicone copolyol, dimethicone copolyol, caprylic/capric triglycerides,
polyglycery1-4
isostearate, cetyl dimethicone copolyol, hcxyl laurate, dimethicone copolyol,
cyclopentasiloxane, and any combination of two or more of these. Preferred
examples of
water-in-silicone emulsifiers include, without limitation, PEG/PPG-18/18
dimethicone (trade
name 5225C, Dow Corning), PEG/PPG-19/19 dimethicone (trade name BY25-337, Dow
Coming), Cetyl PEG/PPG-10/1 dimethicone (trade name Abil EM-90, Goldschmidt
Chemical Corporation), PEG-12 dimethicone (trade name SF 1288, General
Electric), lauryl
PEG/PPG-18/18 methicone (trade name 5200 FORMULATION AID, Dow Corning), PEG-
12 dimethicone crosspolymer (trade name 9010 and 9011 silicone elastomer
blend, Dow
Corning), PEG-10 dimethicone crosspolymer (trade name KSG-20, Shin-Etsu),
dimethicone
PEG-10/15 crosspolymer (trade name KSG-210, Shin-Etsu), and dimethicone PEG-7
isostearate. The water-in-silicone emulsifiers typically will be present in
the composition in
an amount from about 0.00104 to about 10% by weight, in particular in an
amount from about
0.01% to about 5% by weight, and more preferably, below 1% by weight.
[01081 The aqueous phase of the emulsion may include one or more
additional
solvents, including lower alcohols, such as ethanol, isopropanol, and the
like. The volatile
solvent may also be a cosmetically acceptable ester such as butyl acetate or
ethyl acetate;
ketones such as acetone or ethyl methyl ketone; or the like.
[0109] The oil-containing phase will typically comprise from about 10%
to about
99%, preferably from about 20% to about 85%, and more preferably from about
30% to
about 70% by weight, based on the total weight of the emulsion, and the
aqueous phase will
42
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
typically comprise from about 1% to about 90%, preferably from about 5% to
about 70%,
and more preferably from about 20% to about 60% by weight of the total
emulsion. The
aqueous phase will typically comprise from about 25% to about 100%, more
typically from
about 50% to about 95% by weight water.
[0110] The compositions may include liposomes. The liposomes may comprise
other
additives or substances and/or may be modified to more specifically reach or
remain at a site
following administration. Additional suitable delivery vehicles include, e.g.,
niosomes,
submicron emulsions, polymeric encapsulants, gels, creams, lotions, and
combinations
thereof.
[0111] The composition may optionally comprise other cosmetic actives and
excipients, obvious to those skilled in the art including, but not limited to,
fillers, emulsifying
agents, surfactants, film formers, chelating agents, such as EDTA, gelling
agents, thickeners,
emollients, humectants, moisturizers, vitamins, minerals, viscosity and/or
rheology modifiers,
sunscreens, retinoids, hormonal compounds, alpha-hydroxy acids, alpha-keto
acids, anti-
mycobacterial agents, antifungal agents, antimicrobials, antivirals,
analgesics, lipidic
compounds, antineoplastics, immune system boosting agents, anti-allergenic
agents, H1 or
H2 antihistamines, anesthetics, antiseptics, insect repellents, skin cooling
compounds, skin
protectants, skin penetration enhancers, exfollients, lubricants, fragrances,
colorants,
hypopigmenting agents, preservatives (e.g., DMDM
Hydantoin/
Iodopropynylbutylcarbonate), stabilizers, pharmaceutical agents,
photostabilizing agents,
neutralizers (e.g., triethanolamine), and mixtures thereof In addition to the
foregoing, the
cosmetic compositions of the invention may contain any other compound for the
treatment of
skin conditions or disorders. Based on the teachings herein, a person skilled
in the art will be
able to select any of these or other materials, and/or in an amount thereof,
such that one or
more of the desired properties of the cosmetic compositions of the instant
invention can be
preserved.
[0112]
Preservatives may include, for example, alcohols, glycols, parabens,
quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing
agents,
antioxidants, halogenated compounds, and combinations thereof. Illustrative
alcohols
include, e.g., phenoxyethanol, isopropyl alcohol, and benzyl alcohol;
illustrative glycols
include, e.g., propylene, butylene, and pentylene glycol; illustrative
parabens (also known as
parahydroxybenzoic acids) include, e.g., methyl, propyl and butyl-parabens;
illustrative
quaternary nitrogen-containing compounds include, e.g., benzalkonium chloride
and
43
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
Quaternium 15; illustrative isothiazolinones include, e.g.,
methylisothiazolinone and
methylchloroisothiazolinone; illustrative aldehyde-releasing agents include,
e.g., DMDM
hydantoin, imidazolidinyl urea, and diazolidinyl urea; illustrative
antioxidants include, e.g.,
butylated hydroxytoluen and tocopherol, and illustrative halogenated compounds
include,
e.g., tri closan and chlorohex i dine di gluc on ate. Additional examples of
preservatives useful
for the purposes of the present invention can be found, for example, in
Steinberg, D.
"Frequency of Use of Preservatives 2001" Cosmet. Toilet. 117, 41-44, (2002)
and,
"Preservative Encyclopedia" Cosmet. Toilet. 117, 80-96 (2002).
[0113]
Colorants may include, for example, organic and inorganic pigments and
pearlescent agents. Suitable inorganic pigments include, but are not limited
to, titanium
oxide, titanium dioxide, zirconium oxide, and cerium oxide, as well as zinc
oxide, iron oxide,
chromium oxide, and ferric blue. Suitable organic pigments include barium,
strontium,
calcium, and aluminium lakes and carbon black. Suitable pearlescent agents
include mica
coated with titanium oxide, with iron oxide, or with natural pigment.
[0114] Various fillers and additional components may be added. Fillers are
normally
present in an amount of about 0 weight % to about 20 weight %, based on the
total weight of
the composition, preferably about 0.1 weight % to about 10 weight %. Suitable
fillers include
without limitation silica, treated silica, talc, zinc stearate, mica, kaolin,
Nylon powders such
as Orgasol' ", polyethylene powder, Teflon'', starch, boron nitride, copolymer
microspheres
such as ExpancelTM (Nobel Industries), PolytrapTM (Dow Corning), and silicone
resin
microbeads (TospearlT" from Toshiba), and the like.
[0115] In some
preferred embodiments, the compositions include at least one other
skin (or hair) lightener, at least one other anti-inflammatory agent, at least
one other anti-lipid
agent; at least one other exfoliating agent, and/or at least one other anti-
aging agent. Other
conventional additives include: vitamin derivatives such as ascorbyl
monopalmitate;
thickeners such as hydroxyalkyl cellulose; gelling agents; and structuring
agents such as
bentonite, smectite, magnesium aluminum silicate and lithium magnesium
silicate. In some
embodiments of the invention, the topical compositions of the present
invention may also
include one or more of the following: an emollient, an optical diffuser, a
sunscreen, and an
antioxidant. These additives may also act as anti-aging agents. Based on the
teachings
herein, a person skilled in the art will be able to select suitable
emollients, optical diffusers,
sunscreens, and/or antioxidants, or any other materials, and/or in an amount
thereof, such that
44
CA 02768653 2016-10-31
one or more of the desired properties of the cosmetic compositions of the
instant invention
can be preserved.
[01161 An emollient provides the functional benefits of enhancing skin
smoothness
and reducing the appearance of fine lines and coarse wrinkles. Examples
include isopropyl
myristate, petrolatum, isopropyl lanolate, silicones (e.g., methicone,
dimethicone), oils,
mineral oils, fatty acid esters, cetyl ethylhexanoate, C12-I5 alkyl benzoate,
isopropyl
isostearate, diisopropyl dimer dillinoeate, or any mixtures thereof. The
emollient may be
preferably present from about 0.1 wt % to about 50 wt% of the total weight of
the
composition.
[01171 An optical diffuser is a particle that changes the surface
optometrics of skin,
resulting in a visual blurring and softening of, for example, lines and
wrinkles. Examples of
optical diffusers that can be used in the present invention include, but are
not limited to,
boron nitride, mica, nylon, polymethylmethacrylate (PMMA), polyurethane
powder, sericite,
TM
silica, silicone powder, talc, Teflon, titanium dioxide, zinc oxide, or any
mixtures thereof.
When present, the optical diffuser may be present from about 0.01 weight % to
about 20
weight % of the total weight of the composition.
[01181 A sunscreen for protecting the skin from damaging ultraviolet rays
may also
be included. Preferred sunscreens are those with a broad range of UVB and LTVA
protection,
TM
such as octocrylenc, avobenzone (Parsol 1789), octyl methoxycinnamate, octyl
salicylate,
oxybenzone, homosylate, benzophenone, camphor derivatives, zinc oxide, and
titanium
dioxide. When present, the sunscreen may comprise from about 0.01 weight % to
about 70
weight % of the composition.
[0119] An antioxidant functions, among other things, to scavenge free
radicals from
skin to protect the skin from environmental aggressors. Examples of
antioxidants that may
be used in the present compositions include compounds having phenolic hydroxy
functions,
such as ascorbic acid and its derivatives/esters; alpha-hydroxyacids; beta-
carotene; catechins;
curcumin; ferulic acid derivatives (e.g. ethyl ferulate and sodium ferulate);
gallic acid
derivatives (e.g., propyl gallate); lycopene; reductic acid; rosmarinic acid;
tannic acid;
tetrahydrocurcumin; tocopherol and its derivatives (e.g., tocopheryl acetate);
uric acid; or any
mixtures thereof. Other suitable antioxidants are those that have one or more
thiol functions
(-SH), in either reduced or non-reduced form, such as glutathione, lipoic
acid, thioglycolic
acid, and other sulfhydryl compounds. The antioxidant may be inorganic, such
as bisulfites,
metabisulfites, sulfites, or other inorganic salts and acids containing
sulfur. Compositions of
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
the present invention may comprise an antioxidant preferably from about 0.001
weight % to
about 10 weight %, and more preferably from about 0.01 weight % to about 5
weight %, of
the total weight of the composition.
EXAMPLES
Example 1. Decrease in Melanin Synthesis by Inhibiting Calcium Influx
[0120] Modified
yeast peptide fractions comprising a zinc-complexed peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to inhibit calcium
influx into
pigment-producing cells. An experiment was designed to measure intracellular
calcium in
B16 melanoma cells using Fluo-4 NW Calcium Assay Kits (Invitrogen) as per
manufacturer's instructions. B16 mouse melanoma cell lines (ATCC, cat. #: CRL-
6475)
were grown in 96-well tissue culture treated dishes in growth medium. Prior to
calcium
treatment, growth medium from the B16 cell cultures was removed and 100 4, of
the dye
loading solution was added quickly to each well of a 96-well plate. Plates
were incubated at
37 C for 30 minutes, then at room temperature for an additional 30 minutes.
Dye buffer was
removed and plates were washed once with 1 X PBS and replaced with an assay
buffer that
contains calcium (and was formed according to the manufacturer's directions)
along with a
test compound. The test compounds used were: 100 uM 2-APB, a known calcium
influx
inhibitor, and modified yeast peptide fractions comprising different
concentrations of zinc-
complexed peptide comprising SEQ ID NO:1, including 0.1% zinc-complexed
peptide. The
vehicle (assay buffer without a test compound) was used as a control.
[0121]
Fluorescence was measured using a micro-plate reader at excitation/ emission
wavelengths of 485nm/530nm, respectively. The reader was set to read
florescence every 30
seconds for a period of 5 minutes. At the end of 5 minutes, calcium ion influx
was stimulated
by the addition of Thapsigargin to the assay buffer, to give a final
concentration of 1 IIM in
each well. Assay buffer without Thapsigargin was used as a negative control.
The
fluorescence micro-plate reader was set to take fluorescence measurements
every 30 seconds
for a period of 30 minutes, again at excitation/emission wavelengths of
485nm/530nm,
respectively. The florescence units were plotted against time (in minutes) to
give a calcium
influx graph. The effect of 2APB or modified peptide fraction versus the
control was
compared using the area under the curve of the calcium influx peak.
[0122] It was
observed that 100 uM 2-APB treatment inhibited calcium entry into the
cells by 86%. Furthermore, it was unexpectedly observed that treatment of B16
pigment cells
46
CA 02768653 2016-10-31
with modified peptide fraction comprising 0.1% zinc-complexed peptide
comprising SEQ ID
NO:1 also inhibited calcium entry into the cells, and did so by about 45%.
[0123] Next, the effects of 2-APB and modified peptide fractions having a
zinc-
complexed peptide comprising SEQ ID NO:1 on melanin synthesis were examined in
B16
cells. B16 mouse melanoma cell lines (ATCC, cat. #: CRL-6475) were grown in 96-
well
tissue culture treated dishes (Falcon) and treated with a test compound to
determine its ability
to modulate pigment formation (melanin synthesis). Specifically, cells were
exposed to 100
p.M 2-APB or modified yeast peptide fractions comprising different
concentrations of zinc-
complexed peptide comprising SEQ ID NO:!, including 1% and 0.1% zinc-complexed
.. peptide, for seven (7) days. Following the treatment period, the level of
melanin synthesized
was quantified using a Packard micro-plate reader at 540nm.
[0124] After quantifying the amount of melanin synthesized, cell
viability was
determined using the MTT conversion method. The MTT conversion method measures
the
reduction of MTT dye from a yellow, water-soluble, tetrazolium salt to a
bluish-purple
insoluble formazan precipatate by NAD(P)H-dependent microsomal dehydrogenase
enzymes,
which only function in viable cells. The intensity of blue color is thus
indicative of cell
viability. After melanin synthesis quantification, the cultures were exposed
to MTT dye
solution with a concentration of 1 mg/ml for three hours. Formazan material
was solubilized
with reagent alcohol (95% ethanol: 5% isopropanol) and shaken on an orbital
shaker for 15
minutes. MTT dye uptake and conversion by viable cells was determined by
measuring the
TM
extracted formazan at 570nm using a Packard micro-plate reader.
[0125] After normalizing to cell viability, total pigmentation then was
calculated, and
expressed as a percent activity of control. It was surprisingly observed that
2-APB inhibited
melanin synthesis by 77%; and the 0.1% and 1% zinc-complexed peptide exhibited
inhibitory
effects of 27% and 52%, respectively, relative to control (p< 0.05). The
results suggest that
compositions comprising modified yeast peptide fractions comprising a metal-
complexed
peptide comprising SEQ ID NO:1 and/or other calcium influx inhibitors, can be
used to
reduce hyper-pigmentation, for example, when topically applied to hyper-
pigmented skin.
Example 2. Decrease in TNFa production by Modified Yeast Peptide Fractions
[0126] Modified yeast peptide fractions comprising a zinc-complexed
peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to decrease TNFa
production,
which is known to be involved in inflammation. Human Epidermal Keratinocyte
cells were
47
CA 02768653 2016-10-31
cultured in growth medium in 6-well plates at 37 C and 5% CO2 for 48 hours.
Cells were
treated with ltnL of growth medium containing 1 Ong/mL of phorbol myristyl
acetate (PMA)
to stimulate Tumor Necrosis Factor alpha (TNFa). Cells were also co-treated
with modified
yeast peptide fractions comprising different concentrations of zinc-complexed
peptide
.. comprising SEQ ID NO:1, including 0.1% and 1% zinc-complexed peptide.
[0127] After 6 hours of incubation at 37 C, culture medium was collected
and
analyzed for levels of TNFa using an ELISA kit (Quantikine Human TNF-
a/TNFSF1A, R&D
Systems). It was observed that treatment with the modified peptide fractions
comprising
0.1% and 1% zinc-complexed peptide comprising SEQ ID NO:1 inhibited the
induction of
TNFa by PMA by 25% and 46%, respectively (p<0.05). The results suggest that
topical
application of compositions comprising modified yeast peptide fractions
comprising a metal-
complexed peptide comprising SEQ ID NO:1 can reduce inflammation and result in
improvements of symptoms associated with inflammatory skin conditions.
Example 3. Decrease in PPAR-y Expression by Modified Yeast Peptide Fractions
[0128] Modified yeast peptide fractions comprising a zinc-complexed
peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to decrease PPAR-y
expression,
which is known to be involved in lipid production and storage. PPAR-y gene
expression was
monitored using a luciferase reporter assay system. This assay system involves
the PPAR-y
promoter sequence linked to the luciferase enzyme coding region. The level of
luciferase
activity is indicative of gene expression activity from the PPAR-y promoter.
The PPAR-y
reporter was constructed by inserting three copies of PPAR element [(AC0)3]
into the pGL3
vector. The constructs then were transfected into CV-I cells.
[0129] CV-1 cells were plated in 24-well plates at a density of 60% in
DMEM media
supplemented with 10% fetal calf serum (delipided). After reaching 85%
confluence, cells
TM
were transfected using a transfection mixture with LipofectAMINE and Plus
Reagent. The
transfection mixture contained the PPAR-y reporter (AC03-tk) construct (100
ng/well), as
well as PPAR-y plasmid (100 ng/well) and a reference plasmid pRL-NULL (10
ng/well).
The plasmid constructs were initially mixed with 20 41 Plus Reagent, diluted
in 750 u1 serum
and antibiotic-free medium for 15 minutes at RT, and then mixed with 30 Al
LipofectAMINE
Reagent, diluted in 5 nil of the same medium, for an additional 15 minutes.
The final
transfection complexes (1.5 ml/per well) were added to a monolayer of CV-1
cells. After a 3
hour-incubation, the media was replaced by normal culture medium and incubated
overnight
in a 37 C humidified incubator with 5.0% CO2.
48
CA 02768653 2016-10-31
[01301 The transfected cells were treated with modified yeast peptide
fractions
comprising different concentrations of zinc-complexed peptide comprising SEQ
ID NO:1,
including a composition comprising 0.004% zinc-complexed peptide. As a
positive control,
cells were treated with ciglitazone at 10 M; as a negative control, cells
were treated with the
vehicle without any stressed yeast extract. The treated cells were cultured
for an additional
24 hours, washed once with phosphate buffered saline, and lysed in 1000.1 cell
lysis buffer by
gently shaking for 30 minutes at room temperature. Cell lysates were collected
by scraping
after a 3 hour-incubation at -80 C. All experiments were conducted in
triplicate and proper
positive or negative controls included.
101311 Luciferase activity was determined with a Dual-Luciferase Reporter
Assay
System (Promega) as described by the manufacturer. This system contained two
substrates,
used to determine the activity of two luciferases sequentially. Firefly
luciferase activity,
which represented the reporter gene activity, was initiated by mixing an
aliquot of lysate (10
IA) with Luciferase Assay Reagent H. Then the firefly luminescence was
quenched and
Renilla luminescence was simultaneously activated by adding Stop & Glo Reagent
to the
sample plate. The ratio of the firefly luminescence signal over Renilla
luminescence signal in
each sample was calculated, and the signal ratios from extract-treated wells
to that from
vehicle-treated wells were recorded as a fold of induction (>1) or suppression
(<1).
[01321 In triplicate tests, the addition of a modified peptide fraction
comprising
0.004% zinc-complexed peptide comprising SEQ ID NO:1 was found to decrease
expression
of the reporter gene by 30% (p<0.05), indicating a 30% decrease in PPAR-y
expression. The
results suggest that topical application of compositions comprising modified
yeast peptide
fractions comprising a metal-complexecl peptide comprising SEQ ID NO:1 can
control lipid
production, for example reducing sebum overproduction and/or cellulite.
Example 4. Increase in Collagen Synthesis by Modified Yeast Peptide Fractions
[0133] Modified yeast peptide fractions comprising a zinc-complexed
peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to increase
synthesis of collagen,
specifically, dermal matrix component procollagen I, which is known to be
reduced in aging
skin. Human dermal fibroblasts (Cascade Biologics) were cultured in 96-well
tissue culture
plates in 200 I growth medium (DMEM, 5% FBS, 1% L-Glut, and 1% antibiotics)
and
incubated for 24 hours at 37 C. Cells were treated with modified yeast peptide
fractions
comprising different concentrations of zinc-complexed peptide comprising SEQ
ID NO:1
49
CA 02768653 2016-10-31
diluted in growth medium, including fractions comprising 0.1% zinc-complexed
peptide
diluted in growth medium, and incubated for 72 hours at 37 C. After this time
period,
conditioned media was collected and assayed for the levels of procollagen I, a
precursor form
of collagen I, as discussed herein.
[0134] Procollagen I was measured
using a solid-phase sandwich ELISA
immunoassay (Procollagen Type-I C-Peptide EIA Kit) purchased from Takata Bin
USA, WI,
USA, following the manufacturer's instructions. A modified yeast peptide
fraction
comprising 0.1% zinc-co mplexed peptide comprising SEQ ID NO: I stimulated
procollagen I
by 20.5%. The results suggest that topical application of compositions
comprising modified
yeast peptide fractions comprising a metal-complexed peptide comprising SEQ ID
NO:1 can
increase collagen synthesis and thus collagen levels in the skin, thereby
forestalling and/or
improving unwanted signs of skin aging.
Example 5. Decrease in Collagenase Activity by Modified Yeast Peptide
Fractions
[01351 Modified yeast peptide
fractions comprising a zinc-complexed peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to decrease
metalloproteinase
activity. Specifically, Enzcheek Gelatinase/Collagenase Assay Kit (E-I2055)
made by
Molecular Probes was used. This assay uses a DQ gelatin substrate that has
been labeled
TM
with Molecular Probes BODIPY FL dye such that the conjugate's fluorescence has
been
quenched. Upon digestion of the collagen substrate, fluorescence is revealed.
The
collagenase used in this assay was metalloproteinase purified from Clostridium
histolyticum.
[01361 Modified yeast peptide
fractions comprising different concentrations of zinc-
complexed peptide comprising SEQ ID NO:1, including 1% zinc-complexed peptide,
were
applied to this assay to determine their ability to inhibit the
metalloproteinase from digesting
the DQ gelatin substrate. A decrease in fluorescent emission from the reaction
mixture is
indicative of inhibition. Reactions were incubated in the dark at room
temperature for one
hour. Readings were taken using a fluorescence micro-plate reader at the
excitation/
emission wavelengths of 485nni/530nm, respectively.
[01371 It was observed that the
modified peptide fractions comprising 1% zinc-
complexed peptide comprising SEQ ID NO:1 decreased metalloproteinase activity
by 20%.
The results suggest that topical application of compositions comprising
modified yeast
peptide fractions comprising a metal-complexed peptide comprising SEQ ID NO:1
can
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
decrease metalloproteinase activity, thereby reducing loss of collagen and
associated
unwanted features of skin aging, e.g., by reducing loss of skin firmness and
plumpness.
Example 6. Increase in Hyaluronic Acid by Modified Yeast Peptide Fractions
[0138] Modified yeast peptide fractions comprising a zinc-complexed peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to increase
hyaluronic acid
production, specifically in dermal fibroblasts. Human dermal fibroblasts
(Cascade Biologics)
were cultured in 96-well tissue culture plates in 200 ul growth medium (DMEM,
5% FBS,
1% L-Glut, and 1% antibiotics) and incubated for 24 hours at 37 C. Cells
treated with
modified yeast peptide fractions comprising different concentrations of zinc-
complexed
peptide comprising SEQ ID NO:1 diluted in growth medium, including fractions
comprising
0.01% zinc-complexed peptide diluted in growth medium, and incubated for 24
hours at
37 C. After this time period, conditioned media was collected and assayed for
the levels of
hyaluronic acid, using an assay kit purchased from Corgenix, Inc., CO, USA,
following the
manufacturer's instructions.
[0139] It was
observed that modified peptide fractions comprising 0.01% zinc-
complexed peptide comprising SEQ ID NO:1 stimulated hyaluronic acid synthesis
by 100%.
The results suggest that topical application of compositions comprising a
modified yeast
peptide fractions comprising a metal-complexed peptide comprising SEQ ID NO:1
can
increase hyaluronic acid production, thereby reducing one or more of the
unwanted features
associated with skin aging, e.g., by improving skin hydration and resiliency.
Example 7. Increase in Kallikreins Activity by Modified Yeast Peptide
Fractions
[0140] Modified
yeast peptide fractions comprising a zinc-complexed peptide
comprising SEQ ID NO:1 were tested in vitro for the ability to increase
enzymatic activity of
a member of the KLK family, specifically, recombinant human (rh) KLK5.
Recombinant
human KLK5 (R&D Systems; Cat No. 1108-SE) was pre-incubated with modified
yeast
peptide fractions comprising different concentrations of zinc-complexed
peptide comprising
SEQ ID NO:1, including 0.1%, 0.01%, and 0.001% zinc-complexed peptide.
Following pre-
treatment, KLK5 activity was assessed by measuring the rate of peptide bond
cleavage of a
synthetic substrate. The substrate was conjugated to a quenched fluorescent
group (Boc-V-P-
R-AMC Fluorogenic Peptide Substrate, R&D Systems, Cat No. ES011), so that upon
cleavage of the adjacent peptide bond, the fluorescence is revealed, resulting
in a
51
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
measureable emission at a wavelength of 612mi when excited at a wavelength of
340nm. An
increase in the fluorescence reading indicates increased rhKLK5 activity.
[0141] It was
observed that modified peptide fractions comprising 0.1%, 0.01%, and
0.001% zinc-complexed peptide comprising SEQ ID NO:1 stimulated KLK5 activity
by
23%, 27% and 31% respectively, surprisingly giving an inverse dose-response.
The results
suggest that topical application of compositions comprising modified yeast
peptide fractions
comprising a metal-complexed peptide comprising SEQ ID NO:1 can increase KLKs
activity,
thereby enhancing exfoliation and reducing one or more unwanted features
associated with
skin aging, e.g., by improving skin luster and/or brightness.
Example 8: Skin Lightening and/or Anti-Aging Essence Formulation
[0142]
Exemplary cosmetic compositions comprising modified yeast peptide
fractions comprising a zinc-complexed peptide comprising SEQ ID NO:1 for
topical
application to the skin are provided below. The compositions are provided in
the form of an
essence that finds use in anti-aging and/or skin lightening applications.
Water qs
Glycerin 2- 10%
Pentylene Glycol 2-5%
Disodium EDTA 0.2%
Sodium polyacrylate 0.2 ¨ 2%
Silica 0.2 ¨ 2%
Zn2'-complexed peptide 0.001- 2%
Phenoxyethanol 0.1-1%
Example 9: Skin Lightening and/or Anti-Aging Essence Formulation
[0143] Further
exemplary cosmetic compositions comprising modified yeast peptide
fractions comprising a zinc-complexed peptide comprising SEQ ID NO:1 for
topical
application to the skin are provided below. The compositions again are
provided in the form
of an essence that finds use in anti-aging and/or skin lightening
applications.
Water qs
Glycerin 2- 10%
Pentylene Glycol 2-5%
Disodium EDTA 0.2%
X an than gum 0.2 ¨ 2%
Silica 0.2 ¨ 2%
Zn2'-complexed peptide 0.001- 2%
Ascorbyl Glucoside 0.001- 2%
Phenoxyethanol 0.1-1%
Example 10: Skin Lightening and/or Anti-Aging Cream Formulation
52
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
[0144]
Exemplary cosmetic compositions comprising modified yeast peptide
fractions comprising a zinc-complexed peptide comprising SEQ ID NO:1 for
topical
application to the skin are provided below. The compositions are provided in
the form of a
cream that finds use in anti-aging and/or skin lightening applications.
Water qs
Glycerin 2- 10%
Disodium EDTA 0.2%
Zn2tcomplexed peptide 0.001- 2%
Ascorbyl Glucoside 0.001- 2%
Tetrahecyldecyl ascorbate 0.00001- 2%
Carrot Root extract 0.001- 2%
Soybean seed extract 0.001- 1%
Carbopol 0.1 ¨ 2%
Lecithin hydrogenated 0.1-1%
Cetyl Caprylate 2- 15%
Phenoxyethanol 0.1-1%
Example 11: Skin Lightening and/or Anti-Aging SPF 20 Day Cream Formulation
[0145]
Exemplary cosmetic compositions comprising modified yeast peptide
fractions comprising a zinc-complexed peptide comprising SEQ ID NO:1 for
topical
application to the skin are provided below. The compositions are provided in
the form of a
daytime cream that finds use in anti-aging and/or skin lightening
applications, and further
provides SPF 20.
Water qs
Glycerin 2- 10%
Disodium EDTA 0.2%
2 tcomplexed pepti Zn de 0.001- 2%
Ascorbyl Glucoside 0.001- 2%
Tetrahecyldecyl ascorbate 0.00001- 2%
Carrot Root extract 0.001-2%
Soybean seed extract 0.001- 1%
Carbopol 0.1 ¨2%
Cetearyl glucoside 0.5- 3%
Ethylhexyl methoxycinnamate 5-10%
Benzophenone-3 1-5%
Octyl Salicylate 3_5%
Butyl Methoxydibenzoylmethane 1-5%
Phenoxyethanol 0.1-1%
Example 12: Exfoliating Foaming Cleanser Formulation
[0146]
Exemplary cosmetic compositions comprising modified yeast peptide
fractions comprising a zinc-complexed peptide comprising SEQ ID NO:1 for
topical
53
CA 02768653 2012-01-18
WO 2011/025635
PCT/US2010/044360
application to the skin are provided below. The compositions are provided in
the form of a
foaming cleanser that further acts to enhance exfoliation during cleansing.
Water qs
Stearic acid 15- 35%
Potassium Hydroxide 4-8%
Zn2'-complexed peptide 0.001- 2%
Phenoxy ethanol 0.1-1%
Example 13: Skin Lightening and/or Anti-Aging Essence Formulation
[0147] Exemplary
cosmetic compositions comprising modified yeast peptide
fractions comprising a complexed peptide comprising SEQ ID NO:1 for topical
application to
the skin are provided below. The compositions are provided in the form of an
essence that
finds use in anti-aging and/or skin lightening applications.
Water qs
Glycerin 2- 10%
Humectant 2-5%
Chelating agent 0.2%
Thickener 0.2 ¨ 2%
Silica 0.2 ¨ 2%
Complexed peptide 0.001- 2%
Preservative 0.1-1%
Various formulations are prepared according this formula where the peptide is
complexed
with calcium (Ca2'), copper (Cu2+), magnesium (Mg2'), manganese (Mn2'), nickel
(Ni2-'), and
iron (Fe2+). Each formulation is topically applied to skin in need of
depig,menting, including
skin affected by hyper-pigmentation.
Example 14: UV-Stressed Yeast Lysates Failed to Decrease in Melanin Synthesis
[0148] UV-stressed
yeast extract failed to demonstrate any significant reduction of
melanin synthesis. Comparative tests for decreasing melanin synthesis in
pigment cells were
conducted for the UV-stressed yeast extracts described in U.S. Pat. No.
5,643,587 and the
modified yeast peptide fractions of the instant invention. When pigment cells
were exposed
to the UV-stressed yeast extract, at concentrations of 0.1%, 0.01% and 0.001%,
melanin
levels changed by +2%, -6% and -8%. These results indicate that this yeast
extract does not
possess the ability to modulate melanin levels in this system.
[0149] On the
other hand, when pigment cells were exposed to modified yeast peptide
fractions comprising 1% and 0.1% zinc-complexed peptide comprising SEQ ID NO:1
of the
54
CA 02768653 2016-10-31
instant invention, there was an appreciable reduction in melanin synthesis
under the same test
conditions. As reported in Example 1 above, the 0.1% and 1% zinc-complexed
peptide
composition inhibited melanin synthesis by 27% and 52%, respectively. The
results indicate
the surprising lightening benefits of the inventive compositions compared with
UV-stressed
.. yeast extracts of the prior art, in particular the melanin synthesis-
decreasing abilities of
modified yeast peptide fractions of UV-stressed yeast extracts containing a
peptide
comprising SEQ ID NO:1 as the dominant fraction and complexed with zinc ions.
[0150] The terms used herein have their ordinary and accustomed meanings in
the art,
unless otherwise specified. All weights percentages referred to herein are
given in terms of
"% by weight" or "weight %" of the total composition, which refers to the
weight percent of
the total formulation after addition of any carriers, solvents, emollients, or
other components
before application to the skin (or hair), unless otherwise indicated.
[0151]
Many modifications
and variations of this invention can be made without departing from its spirit
and scope, as
will be apparent to those skilled in the art. The specific embodiments
described herein are
offered by way of example only, and the invention is to be limited only by the
terms of the
appended claims, along with the full scope of equivalents to which such claims
are entitled.
